WO2020024056A1 - Compositions comprising cannabinoids and absorbable material and uses thereof - Google Patents

Abstract

The present technology generally relates to a composition for topical administration or for oral administrations. The composition comprises at least one cannabinoid and at least one absorbable material. In some instances, the at least one cannabinoid is isolated from Cannabis indica.

Description

COMPOSITIONS COMPRISING CANNABINOIDS AND ABSORBABLE

MATERIAL AND USES THEREOF

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims the benefit of and priority to U.S. provisional application No. 62/713316, filed on August 1* 2018, and to U.S. provisional application No. 62/827,284, filed on April 1* 2019, the content of which is herein incorporated in entirety by reference.

FIELD OF TECHNOLOGY

[0002] The present technology generally relates to compositions comprising caimahinnids that are suitable for topical administration and/or oral administration as well as to methods for preparing and administering such compositions. In particular, the present technology generally relates to compositions comprising cannahinoids and absorbable materials that are suitable for topical administration and oral administration as well as to methods for preparing and administering such compositions.

BACKGROUND INFORMATION

[0003] Cannabis has a long history of being consumed for many purposes and in many forms. The psychoactive effects of caimahis are well known, however the medical benefits are just beginning to be uncovered and exploited.

[0004] Currently there are over 480 identified compounds found in cannabis. The better known compound is tetrahydrocamiabniol (THC). THC is responsible for maty of the psychoactive effects as well as the medicinal effects. Cannahidiol (CBD) is also another major compound found in caimahis comprising up to 40% of the total carmabinoids found in cannabis extracts and could have as many health benefits as THC.

[0005] The system (ECS) is a biological system composed of i, which are endogenous lipid-based retrograde neurotransmittera that bind to caimahinoid receptors, and caimahinoid receptor proteins that are expressed throughout the mammalian central nervous system and peripheral nervous system. The eadocamabinoid system is involved in regulating a variety of physiological and cognitive processes including fertility, pregnancy, during pre- and postnatal development, appetite, pain-sensation, mood, and memory, and in mediating the pharmacological effectB of cannabis· Recent studies have suggested the existence of a functional ECS in the skin and implicated it in various biological processes (e.g., proliferation, growth, differentiation, apoptosis and cytokine, mediator or hormone production of various cell types of the skin and appendages, such as the hair follicle and sebaceous gland). It would appear that an important physiological function of the cutaneous ECS is to constitutivdy control the proper and well-balanced proliferation, differentiation and survival, as well as immune competence and/or tolerance, of skin cells. The disruption of this delicate balance might facilitate the development of multiple pathological conditions and diseases of the skin (e.g., acne, seborrhea, allergic dermatitis, itch and pain, psoriasis, hair growth disorders, systemic sclerosis and cancer). It is envisaged that the targeted manipulation of the ECS (aiming to normalize the unwanted skin cell growth, sebum production and skin inflammation) might be beneficial in a multitude of human skin diseases and skin conditions.

[0006] In view of this, it would be desirable to obtain compositions for efficiently delivering cannabinoids to cells of, for example, skin tissues to achieve at least some of the beneficial effects of cannabinoids.

SUMMARY OF DISCLOSURE

[0007] Acording to various aspects, the present technology relates to a composition, wherein the composition comprises at least one cannabinoid and at least at least one absorbable material. In some instances, the at least one cannabinoid is isolated from Cannabis or is synthethically derived. According to various aspects, the present technology relates to a composition, wherein the composition comprises at least one cannabinoid and at least one absorbable material, wherein the cannabinoid in not from hemp seed extract. In certain embodiments, the at least one cannabinoid is tetrahydrocannabinol (THC). In certain embodiments, the at least one cannabinoid is cannabidiol (CBD). In certain embodiments, the at least one cannabinoid is a mixture of THC and CBD.

[0008] In certain embodiments, the compositions are used for diminishing the effects of skin aging, preventing the effects of skin aging, or for both, in a subject. In certain embodiments, the compositions are used for achieving skin rejuvenation in a subject. In certain embodiments, the compositions are used for prevention and/or treatment of acne in a subject. In certain embodiments, the compositions are used for prevention and/or treatment of atopic dermatitis in a subject. In certain embodiments, the compositions are used for treatment of allergies in a subject. In certain embodiments, the compositions are used for treatment of skin allergy. In certain embodiments, the compositions are used for reduction of hair loss and/or promoting of hair growth in a subject. In certain embodiments, the compositions are used for reduction of pain. In certain embodiments, the compositions are used for reduction joint pain.

[0009] According to various aspects, the present technology relates to a method for diminishing the effects of skin aging, preventing the effects of skin aging, or for both, in a subject; the method comprising topically administering a composition as defined herein to the subject.

[0010] According to various aspects, the present technology relates to a method for achieving skin rejuvenation in a subject; the method comprising topically administering a composition as defined herein to the subject. According to various aspects, the present technology relates to a method for preventing or treating acne in a subject, the method comprising topically administering a composition as defined herein to the subject. According to various aspects, the present technology relates to a method for preventing or treating atopic dermatitis in a subject, the method comprising topically administering a composition as defined herein to the subject. According to various aspects, the present technology relates to a method for treating allergies in a subject, the method comprising intranasally administering a composition as defined herein to the subject. According to various aspects, the present technology relates to a method for reducing hair loss and promoting hair growth in a subject, the method comprising topically administering a composition as defined herein to the subject. According to various aspects, the present technology relates to a method for reducing pain in a subject, the method comprising orally administering a composition as defined herein to the subject.

[0011] According to various aspects, the present technology relates to a beverage, wherein the beverage comprises at least one cannabinoid, and at least one absorbable. In some instances, the at least one cannabinoid is isolated from Cannabis or is synthetically derived. In some further instances, the at least one absorbable material is a glycosaminoglycan, such as, hyaluronic acid or a salt thereof.

[0012] According to various aspects, the present technology relates to a composition, wherein the composition comprises at least one cannabinoid, at least one absorbable material, at least one terpene, and at least one botanical extract. In some instances, the at least one cannabinoid is isolated from Cannabis or is synthetically derived. In some further instances, the at least one absorbable material is a glycosaminoglycan, such as, hyaluronic acid or a salt thereof.

[0013] Other aspects and features of the present technology will become apparent to those ordinarily skilled in the art upon review of the following description of specific embodiments.

BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Reference will now be made to the accompanying drawings.

[0015] Fig. 1 illustrates the terpene profile and related concentrations of the terpenes present in a cannabis oil used in the preparation of compositions of the present technology. The profile and concentrations were assesed by liquid chromatography electrospray ionization mass spectrometry (LC-ESI-MSMS), and ultra perffomance liquid chromatography coupled with UV detectors (UPLC- UV).

DETAILED DESCRIPTION

[0016] The present technology is explained in greater detail below. This description is not intended to be a detailed catalog of all the different ways in which the technology may be implemented, or all the features that may be added to the instant technology. For example, features illustrated with respect to one embodiment may be incorporated into other embodiments, and features illustrated with respect to a particular embodiment may be deleted from that embodiment. In addition, numerous variations and additions to the various embodiments suggested herein will be apparent to those skilled in the art in light of the instant disclosure which variations and additions do not depart from the present technology. Hence, the following description is intended to illustrate some particular embodiments of the technology, and not to exhaustively specify all permutations, combinations and variations thereof.

[0017] As used herein, the singular form“a,”“an” and“the” include plural referents unless the context clearly dictates otherwise.

[0018] The recitation herein of numerical ranges by endpoints is intended to include all numbers subsumed within that range (e.g., a recitation of 1 to 5 includes 1, 1.25, 1.33, 1.5, 2, 2.75, 3, 3.80, 4, 4.32, and 5).

[0019] The tom“about” is used herein explicitly or not, every quantity given herein is meant to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including equivalents and approximations due to the experimental and/or measurement conditions for such given value. For example, the term“about” in the context of a given value or range refers to a value or range that is within 20%, preferably within 15%, more preferably within 10%, more preferably within 9%, more preferably within 8%, more preferably within 7%, more preferably within 6%, and more preferably within 5% of the given value or range.

[0020] The expression“and/or” where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. For example“A and/or B” is to be taken as specific disclosure of each of (i) A, (ii) B and (iii) A and B, just as if each is set out individually herein.

[0021] The terms “composition” and “formulation” as used interchangeably herein are equivalent terms referring to a composition of matter.

[0022] As used herein, the term“cannabinoid” refers to a class of diverse chemical compounds that act on cannabinoid receptors on cells that repress neurotransmitter release in the brain. These receptor proteins include the endocannabinoids (produced naturally in the body by humans and animals), the phytocannabinoids (found in cannabis and some other plants), and synthetic cannabinoids.

[0023] As used herein, the term“terpene” refers to a class of organic compounds, naturally produced by a variety of plants. Although sometimes used interchangeably with“terpenes”, terpenoids (or isoprenoids) are modified terpene as they containing additional functional groups, usually oxygen-containing. Terpenes are the major components of rosin and of turpentine produced from resin. Terpenes are also major biosynthetic building blocks. Steroids, for example, are derivatives of the triterpene squalene. Terpenes and terpenoids are the primary constituents of the botanical extracts of many types of medicinal plants and flowers. Examples of terpenes found in cannabis, include, but are not limited to: myrcene, limonene, caryophyllene, pinene, ocimene, terpinolene, humulene, sabinene, cineole, terpinene, pulegone, terpineol, bomyl acetate, copaene, alloaromadendrene, viridiflorene, bisabolene, cadinene, amesene, transnerolidol, and bisabolol. Terpenes are also available in synthetic form.

[0024] As used herein, the term“cannabidiol (CBD)” refers to a cannabinoid found in cannabis.

CBD is a major phytocannabinoid, accounting for up to 40% of the total phytocannabinoids found in the plant's extract. (THC). CBD has a very low affinity for CB1 and CB2 receptors but acts as an indirect antagonist of their agonists. CBD may potentiate THC's effects by increasing CB1 receptor density or through another CB1 -related mechanism. It is also an inverse agonist of CB2 receptors. CBD possesses antiproliferative, pro-apoptotic effects and inhibits cancer cell migration, adhesion and invasion. The IUPAC nomenclature for CBD is 2-((lS,6S)-3-methyl-6-(prop-l-en-2-yl)cyclo- hex-2-enyl)-5-pentylbenzene-l ,3-diol).

[0025] As used herein, the term “tetrahydrocannabinol (THC)” refers to the principal psychoactive constituent (or cannabinoid) of the cannabis plant. THC has a partial agonist activity at the cannabinoid receptor CB1, and the CB2 receptor. IUPAC nomenclature for THC is (-)- (6aR,lQaR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-l-ol.

[0026] Die expression“cannabinoid receptor” refers hereinafter to a class of cell membrane receptors under the G protein-coupled receptor superfamily. There are currently two known subtypes of cannabinoid receptors, termed CB1 and CB2. Die CB1 receptor is expressed in the brain, the lungs, the liver, the kidneys, and throughout the body. The CB2 receptor is expressed mainly in the immune system and in hematopoietic cells. The expression“Cannabinoid receptor type 1 (CB1)” refers hereinafter to a G protein-coupled cannabinoid receptor located primarily in the central and peripheral nervous system. It is activated by the endocannabinoid neurotransmitters anandamide and 2-arachidonoyl glyceride (2-AG); by plant cannabinoids, such as the compound THC, an active ingredient of the psychoactive drug cannabis; and by synthetic analogues of THC. The expression “Cannabinoid receptor type 2 (CB2)” refers hereinafter to a G protein-coupled receptor from the cannabinoid receptor family that in humans is encoded by the CNR2 gene. It is closely related to the cannabinoid receptor type 1, which is largely responsible for the efficacy of endocannabinoid- mediated presynaptic-inhibition, the psychoactive properties of Tetrahydrocannabinol, the active agent in marijuana, and other phytocannabinoids (natural cannabinoids). The principal endogenous ligand for the CB2 receptor is 2-arachidonoylglycerol (2-AG). [0027] As used herein, the expression“cannabis strain” refers to varieties of the plant genus Cannabis, which encompasses the species Cannabis sativa, Cannabis indica and Cannabis ruderalis. Varieties are developed to intensify specific characteristics of the plant, or to differentiate the strain for the purposes of marketing or to make it more effective as a drug. Cannabis strains commonly refer to those varieties with recreational and medicinal use. These varieties have been cultivated to contain a high percentage of cannabinoids.

[0028] The expression“THC elevated cannabis” or“elevated levels of THC” or any variations thereof refers hereinafter to a cannabis having about 5% or more THC.

[0029] The expression“CBD elevated cannabis” or“elevated levels of CBD” or any variations thereof refers hereinafter to refers hereinafter to a cannabis having about 4% or more CBD.

[0030] The term“topical” as used herein means as applied to body surfaces, such as the skin, hair and nails.

[0031] As used herein, the term“epidermis” refers to the outer layer of the three layers that make up the skin, the inner layers being the dermis and hypodermis. The epidermis layer provides a barrier to infection from environmental pathogens and regulates the amount of water released from the body into the atmosphere through transepidermal water loss. The outermost part of the epidermis is composed of stratified layers of flattened cells, that overlies a basal layer (stratum basale) composed of columnar cells arranged perpendicularly. As used herein, the term“dermis” refers to the thick layer of living tissue below the epidermis that forms the true skin, containing blood capillaries, nerve endings, sweat glands, hair follicles, and other structures.

[0032] As used herein, the expression“soft tissue” refers to tissues that connect, support, or surround other structures and organs of the body, not being bone. Soft tissue includes tendons, ligaments, fascia, skin, fibrous tissues, fat, axilla, and synovial membranes (which are connective tissue), and muscles, nerves and blood vessels (which are not connective tissue).

[0033] The expression“absorbable material” when used herein means a material that may be absorbed by soft tissue such as skin and that may penetrate into the layers of the skin.

[0034] As used herein, the term“glycosaminoglycan” refers long unbranched polysaccharides consisting of a repeating disaccharide unit. The repeating unit (except for keratan) consists of an amino sugar (N-acetylglucosamine or N-acetylgalactosamine) along with a uronic sugar (glucuronic acid or iduronic acid) or galactose.

[0035] The present technology stems from results of experiments conducted in order to improve overall delivery of cannabinoids to deeper layers of the skin. The experiments performed demonstrated that the combination of cannabinoids with an absorbable material allows for a more efficient delivery of the cannabinoids to deeper layers of the skin.. [0036] Die present technology further stems from results of experiments conducted in order to validate the oral delivery of cannabinoids accordinging to embodiments of the present technology. The experiments performed demonstrated that the combination of cannabinoids with an absorbable material allows for a more efficient metabolization when orally administered, demonstrated short onset times and time to effect, long duration and high intensity of the desired effect following consumption.

[0037] In some embodiments, the present technology relates to a composition comprising at least one cannabinoid and at least one absorbable material for topical administration to the skin. In some instances, the composition of the present technology is a cosmetic composition. In some implementations of these embodiments, the at least one cannabinoid is tetrahydrocannabinol (THC) or a derivative thereof. In some implementations of these embodiments, the at least one cannabinoid is cannabidiol (CBD) or a derivative thereof. In some implementations of these embodiments, the at least one cannabinoid is tetrahydrocannabinol (THC) or a derivative thereof and cannabidiol (CBD) or a derivative thereof. In some further implementations, the at least one absorbable material is a glycosaminoglycan.

[0038] In some embodiments, the present technology relates to a composition comprising at least one cannabinoid and at least one absorbable material for absorption by skin cells. In some instances, the composition of the present technology is a cosmetic composition. In some implementations of these embodiments, the at least one cannabinoid is tetrahydrocannabinol (THC) or a derivative thereof. In some implementations of these embodiments, the at least one cannabinoid is cannabidiol (CBD) or a derivative thereof. In some implementations of these embodiments, the at least one cannabinoid is tetrahydrocannabinol (THC) or a derivative thereof and cannabidiol (CBD) or a derivative thereof. In some further implementations, the at least one absorbable material is a glycosaminoglycan.

[0039] In some embodiments, the present technology relates to a composition comprising at least one cannabinoid and at least one absorbable material for oral administration. In some implementations of these embodiments, the at least one cannabinoid is tetrahydrocannabinol (THC) or a derivative thereof. In some implementations of these embodiments, the at least one cannabinoid is cannabidiol (CBD) or a derivative thereof. In some implementations of these embodiments, the at least one cannabinoid is tetrahydrocannabinol (THC) or a derivative thereof and cannabidiol (CBD) or a derivative thereof. In some further implementations, the at least one absorbable material is a glycosaminoglycan.

i) Cannabinoids [0040] The cannabis plant has many naturally occurring substances that are of interest in the fields of science and medicine. Isolated compounds from the cannabis plant include D9- tetrahydrocannabinol (THC), cannabidiol (CBD), cannabichromene (CBC), cannabigerol (CBG), cannabinol (CBN), cannabidivarin (CBDV), among other compounds, cannabigerolic acid (CBGA), cannabigerolic acid monomethylether (CBGAM), cannabigerol monoethylether (CBGM), cannabigerovarinic acid (CBGVA), cannabigerovarin (CBGV), cannabichromemic acic (CBCA), cannabichromevarinic acid (CBCVA), cannabichromevarin (CBCV), cannabidiolic acid (CBDA), cannabidiol monoethylether (CBDM), cannabidiol-C₄ (CBD-C₄), cannabidivarinic acid (CBDV A), cannabidiorcol (CBD-Ci), delta-9-tetrahydrocannabinolic acid A (THCA-A), delta-9- tetrahydrocannabinolic acid B (THCA-B), delta-9-tetrahydrocannabinolic acid-C₄ (THCA-C₄), delta- 9-tetrahydrocannabivarinic acid (THCVA), delta-9-tetrahydrocannabivarin (THCV), delta-9- tetrahydrocannabiorcolic acid (THCA-Ci), delta-9-tetrahydrocannabiorcol (THC-Ci), delta-7-m- iso-tetrahydrocannabivarin, delta-8-tetrahydrocannabinolic acid (A⁸-THCA), delta-8- tetrahydrocannabinol (A⁸-THC), cannabicyclolic acid (CBLA), cannabicyclol (CBL), cannabicyclovarin (CBLV), cannabielsoic acid A (CBEA-A), cannabielsoic acid B (CBEA-B), cannabieksoin (CBE)m cannabinolic acid (CBNA), cannabinol methylether (CBNM), cannabinol-C₄ (CBN-C₄), cannabivarin (CBV), cannabinol-C₂ (CBN-C₂), cannabiorcol (CBN-Ci), cannabinodiol (CBND), cannabinodivarin (CBVD), cannabitriol (CBT), 10-ethoxy-9-hydroxy-delta-6a- tetrahydrocannabinol, 8,9-dihydroxy-delta-6a-tetrahydrocannabinol, cannabitriolvarin (CBTV), ethoxy-cannabitriolvarin (CBTVE), dehydrocannabifuran (DCBF), cannabifuran (CBF), cannabichromanon (CBCN), cannabicitran (CBT), 10-oxo-delta-6a-tetrahydrocannabinol (OTHC), delta-9-m-tetrahydrocannabinol (m-THC), 3,4,5,6-tetrahydro-7-hydroxy-alpha-alpha-2-trimethyl- 9-n-propyl-2,6-methano-2H-l-benzoxocin-5-methanol (OH-iso-HHCV), cannabiripsol (CBR), and trihydroxy-delta-9-tetrahydrocannabinol (triOH-THC).

[0041] Depending on the combination of cannabis strains that the concentrated cannabis isolate or extract is obtained from, each batch of concentrated cannabis isolate or extract has a different CBD to THC ratio. Besides the CBD and THC content, concentrated cannabis isolate or extract used in the compositions of the present technology take into account the perceived psychoactive effects of the species of cannabis plants used, particularly cannabis indica.

[0042] As used herein, the expression“CBD:THC ratio” or“THC:CBD ratio” refers to the amount of CBD and THC that is comprised in any the compositions of the present technology. THC dominant options (0:1) will provide varying degrees of psychoactivity. A 1:3 ratio of CBD to THC results in a some psychoactivity while minimizing THC's unwanted side effects, producing a calming sensation with reduced anxiety, stress relief and exhibiting anti-inflammatory properties. This ratio can act an as advanced pain relievo- with the synergistic benefits CBD and THC provide. A ratio of equal parts CBD to THC (1:1) is considered highly effective for pain relief, anxiety, spasticity, fibromyalgia, insomnia, nausea and appetite stimulation. This ratio shows promise in relieving symptoms associated with Multiple Scloosis and may be able to kill certain cancer cells and inhibit tumor growth. Higher CBD options, such as 2:1 or 3:1, may be an ideal ratio for combating autoimmune disorders, gastrointestinal issues such as Crohn's and colitis, arthritis, and psoriasis with little to no psychoactivity. CBD dominant ratios of 25:1 or 1:0 offer no psychoactivity and may be most effective for curbing high anxiety, depression, seizures, psychosis, PTSD, and neurodegenerative conditions such as Parkinson's and Huntington's Disease.

[0043] In some embodiments, the composition of the present technology comprises cannbinoids from Cannabis indica. The properties of Cannabis indica include, but are not limited to, increase mental relaxation, increase muscle relaxation, decrease nausea, decrease acute pain, increase appetite, and increase dopamine.

[0044] In one embodiment, the compositions of the present technology comprise CBD in an amount ranging from between about 0.001 wt% to about 99.999 wt%, between about 0.001 wt% and about 90 wt%, between about 0.01 wt% and about 90 wt%, between about 0.1% wt% and about 90 wt%, between about 0.001 wt% to about 75 wt%, between about 0.001% and about 75 wt%, between about 0.01 wt% and about 75 wt%, between about 0.1% wt% and about 75 wt%, between about 0.001 wt% to about 50 wt%, between about 0.001 wt% and about 50 wt%, between about 0.01 wt% and about 50 wt%, between about 0.1% wt% and about 50 wt%, between about 0.001 wt% to about 25 wt%, between about 0.001 wt% and about 25 wt%, between about 0.01 wt% and about 25 wt%, between about 0.1% wt% and about 25 wt%, between about 0.001 wt% and about 20 wt% of the total weight of the composition. In some implementations, the cannabidiol (CBD) or a derivative thereof is selected from CBD, CBDV, CBDA and any combination thereof and wherein the CBD or a derivative thereof is selected from natural CBD or a derivative thereof produced in the body of humans and animals, CBD or a derivative thereof extracted from plants, synthetic CBD or a derivative thereof, and any combination thereof.

[0045] In one embodiment, the compositions of the present technology comprise THC in an amount ranging from between about 0.001 wt% to about 99.999 wt%, between about 0.001 wt% and about 90 wt%, between about 0.01 wt% and about 90 wt%, between about 0.1% wt% and about 90 wt%, between about 0.001 wt% to about 75 wt%, between about 0.001% and about 75 wt%, between about 0.01 wt% and about 75 wt%, between about 0.1% wt% and about 75 wt%, between about 0.001 wt% to about 50 wt%, between about 0.001 wt% and about 50 wt%, between about 0.01 wt% and about 50 wt%, between about 0.1% wt% and about 50 wt%, between about 0.001 wt% to about 25 wt%, between about 0.001 wt% and about 25 wt%, between about 0.01 wt% and about 25 wt%, between about 0.1% wt% and about 25 wt%, between about 0.001 wt% and about 30 wt% of the total weight of the composition. In some implementations, the THC or a derivative thereof is selected from: THC, THCV, THCA, THCVA and any combination thereof.

[0046] In some embodiments, a composition of the present technology comprising a high THC, low CBD content comprises between about 10% and about 99% THC and trace amounts of CBD. In some embodiments, a composition of the present technology comprising a balanced CBD/THC content comprises between about 5% and about 15% THC and between about 5% and about 15% CBD. In some embodiments, a composition of the present technology comprising a high CBD, low THC content comprises between about 5% and about 99% CBD and under about 5% THC.

[0047] Cannabinoids can be isolated by extraction or cold pressing from cannabis plants. Cannabinoids are also available in synthetic forms. Methods to synthesize cannabinoids in lab settings were discovered and are still currently practiced. Synthetic cannabinoids are more targeted, in that the synthetic compound usually comes isolated without other cannabinoids mixed in. Methods for isolating cannabinoids or other components of cannabis are well known in the art.

[0048] In various embodiments, the cannabinoids are obtained from at least one cannabis plant

This plant may be either a CBD rich strain, such as: Snow Dome, Tower, Avidekel, Fedora 17,

ACDC, or it may be a THC rich strain, such as Black Destroyer, Critical Neville Haze, Mataro Blue, LSD OG Kush, Pineapple Chunk, Blue Monster Hoik, Y Griega, Satori, Tutankhamon. It will be appreciated that the cannabinoids may be obtained from other cannabis strains without departing from the present technology.

[0049] In one embodiment, the compositions of the present technology comprise a THC:CBD ratio of about 1:1, about 1.25:1, 1:1.25, 1.5:1, about 1:1.5, about 1.75:1, about 1:1.75, about 1:2, or about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 10:1 to about 300:1, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, or about 1:10 to about 1:300.

[0050] In one embodiment, the CBD:THC ratio is between about 1:1 and about 1:550. In one embodiment the CBD:THC ratio is betwen 1:1 to 1:500. In one embodiment the CBD:THC ratio is betwen 1:1 to 1:450. In one embodiment the CBD:THC ratio is betwen 1:1 to 1:400. In one embodiment the CBD:THC ratio is betwen 1:1 to 1:350. In one embodiment the CBD:THC ratio is betwen 1:1 to 1:300. In one embodiment the CBD:THC ratio is betwen 1:1 to 1:250. In one embodiment the CBD:THC ratio is betwen 1:1 to 1:200. In one embodiment the CBD:THC ratio is betwen 1:1 to 1:150. In one embodiment the CBD:THC ratio is betwen 1:100 to 1:500. In one embodiment the CBD:THC ratio is betwen 1:100 to 1:450. In one embodiment the CBD:THC ratio ls betwen 1 : 100 to 1 :400. In one embodiment the CBD:THC ratio is betwen 1 : 100 to 1 :350. In one embodiment the CBD:THC ratio is betwen 1:100 to 1:300. In one embodiment the CBD:THC ratio is betwen 1:100 to 1:250. In one embodiment the CBD:THC ratio is betwen 1:100 to 1:200. In one embodiment the CBD:THC ratio is betwen 1:100 to 1:150. In one embodiment the CBD:THC ratio is betwen 1:1 to 1:100. In one embodiment, the CBD:THC ratio is between about 1:1 and about 1:80. In one embodiment, the CBD:THC ratio is between about 1:1 and about 1:60. In one embodiment, the CBD:THC ratio is between about 1:1 and about 1:40. In one embodiment, the CBD:THC ratio is between about 1:1 and about 1:20. In one embodiment, the CBD:THC ratio is between about 1:1 and about 1:10. In one embodiment, the CBD:THC ratio is between about 1:10 and about 1:100. In one embodiment, the CBD:THC ratio is between about 1:10 and about 1:80. In one embodiment, the CBD:THC ratio is between about 1:10 and about 1:60. In one embodiment, the CBD:THC ratio is between about 1:10 and about 1:40. In one embodiment, the CBD:THC ratio is between about 1:10 and about 1:20. In one embodiment, the CBD:THC ratio is between about 1:1 and about 10:1. The ratio may be any ratio or range within the stated ranges, including endpoints.

[0051] In various embodiments provided herein, percent refers to percent by weight. In one embodiment, the cannabis isolate or extract comprises about 95% or more of at least one desired cannabinoid and/or terpene. In one embodiment, the cannabis isolate or extract comprises about 90% or more of at least one desired cannabinoid and/or terpene. In one embodiment, the cannabis isolate or extract comprises about 80% or more of at least one desired cannabinoid and/or terpene. In one embodiment, the cannabis isolate or extract comprises about 70% or more of at least one desired cannabinoid and/or terpene. In one embodiment, the cannabis isolate or extract comprises about 60% or more of at least one desired cannabinoid and/or terpene. In one embodiment, the cannabis isolate or extract comprises about 50% or more of at least one desired cannabinoid and/or terpene. In one embodiment, the cannabis isolate or extract comprises about 40% or more of at least one desired cannabinoid and/or terpene. In one embodiment, the cannabis isolate or extract comprises about 30% or more of at least one desired cannabinoid and/or terpene. In one embodiment, the cannabis isolate or extract comprises about 20% or more of at least one desired cannabinoid and/or terpene. In one embodiment, the cannabis isolate or extract comprises about 10% or more of at least one desired cannabinoid and/or terpene. In one embodiment, the cannabis isolate or extract comprises about 5% or more of at least one desired cannabinoid and/or terpene. In one embodiment, the cannabis isolate or extract comprises about 1% or more of at least one desired cannabinoid and/or terpene. In one embodiment, the cannabis isolate or extract comprises about 0.1% or more of at least one desired cannabinoid and/or terpene. In one embodiment, the cannabis isolate or extract comprises about 0.01% or more of at least one desired cannabinoid and/or terpene. In one embodiment, the cannabis isolate or extract comprises about 0.001% or more of at least one desired cannabinoid and/or terpene. In one aspect, the cannabis isolate or extract is diluted to a desired cannabinoid and/or terpene concentration.

[0052] Examples of terpenes that may be used in the methods of the present technology include, but are not limited to: 7,8-dihydroionone, Acetanisole, Acetic Acid, Acetyl Cedrene, Anethole, Anisole, Benzaldehyde, Bergamotene (a-cis-Bergamotene) (a-trans-Bergamotene), Bisabolol (□- Bisabolol), Bomeol, Bomyl Acetate, Butanoic/Butyric Acid, Cadinene (a-Cadinene) (g-Cadinene), Cafestol, Caffeic acid, Camphene, Camphor, Capsaicin, Carene (D-3-Carene), Carotene, Carvacrol, Carvone, Dextro-Carvone, Laevo-Carvone, Caiyophyllene (b-Caryophyllene), Caryophyllene oxide, Castoreum Absolute, Cedrene (a-Cedrene) (b-Cedrene), Cedrene Epoxide (a-Cedrene Epoxide), Cedrol, Cembrene, Chlorogenic Add, Cinnamaldehyde (a-amyl-Cinnamaldehyde) (a-hexyl- Cinnamaldehyde), Cinnamic Acid, Cinnamyl Alcohol, Citronellal, Citronellol, a-Copaene, Cryptone, Curcumene (a-Curcumene) (g-Curcumene), Decanal, Ddiydrovomifoliol, Diallyl Disulfide, Dihydroactinidiolide, Dimethyl Disulfide, Eicosane/lcosane, Elemene (b-Elemene), Estragole, Ethyl acetate, Ethyl Cinnamate, Ethyl maltol, Eucalyptol/l,8-Cineole, Eudesmol (a- Eudesmol) (b-Eudesmol) (g-Eudesmol), Eugenol, Euphol, Famesene, Famesol, Fenchol (b-Fenchol), Fenchone, Geraniol, Geranyl acetate, Germacrenes, Germacrene B, Guaia-l (10), 11-diene, Guaiacol, Guaiene (a-Guaiene), Gmjunene (a-Gmjunene), Hemiarin, Hexanaldehyde, Hexanoic Acid, Humulene (a-Humulene) (b-Humulene), lonol (3-oxo-a-ionol) (b-ΐohoΐ), lonone (a-lonone) (b- lonone), Ipsdienol, Isoamyl acetate, Isoamyl Alcohol, Isoamyl Formate, Isobomeol, Isomyrcenol, Isopulegol, Isovaleric Acid, Isoprene, Kahweol, Lavandulol, Limonene, g-Linolenic Acid, Linalool, Longifolene, a-Longipinene, Lycopene, Menthol, Methyl butyrate, 3-Mercapto-2-Methylpentanal, Mercaptan/Thiols, b-Mercaptoethanol, Mercaptoacetic Acid, Allyl Mercaptan, Benzyl Mercaptan, Butyl Mercaptan, Ethyl Mercaptan, Methyl Mercaptan, Furfuryl Mercaptan, Ethylene Mercaptan, Propyl Mercaptan, Thenyl Mercaptan, Methyl Salicylate, Methylbutenol, Methyl-2-Methylvalerate, Methyl Thiobutyrate, Myrcene (b-Myrcene), g-Muurolene, Nepetalactone, Nerol, Nerolidol, Neryl acetate, Nonanaldehyde, Nonanoic Acid, Ocimene, Octanal, Octanoic Acid, P-cymene, Pentyl butyrate, Phellandrene, Phenylacetaldehyde, Phenylethanethiol, Phenylacetic Acid, Phytol, Pinene, b-Pinene, Propanethiol, Pristimerin, Pulegone, Quercetin, Retinol, Rutin, Sabinene, Sabinene Hydrate, cis-Sabinene Hydrate, trans-Sabinene Hydrate, Safranal, a-Selinene, a-Sinensal, b- Sinensal, b-Sitosterol, Squalene, Taxadiene, Terpin hydrate, Terpineol, Terpine-4-ol, a-Terpinene, g- Terpinene, Terpinolene, Thiophenol, Thujone, Thymol, a-Tocopherol, Tonka Undecanone, Undecanal, Valeraldehyde/Pentanal, Verdoxan, a-Ylangene, Umbelliferone, and Vanillin. [0053] In some embodiments, the CBD or the derivative thereof present in the compositions of the present technology interacts with at least one receptor selected from a group consisting of Cannabinoid receptor type 1 (CB1), Cannabinoid receptor type 2 (CB2), and any combination thereof. In some embodiments, the THC or the derivative thereof present in the compositions of the present technology interacts with at least one receptor selected from a group consisting of Cannabinoid receptor type 1 (CB1), Cannabinoid receptor type 2 (CB2), and any combination thereof.

[0054] In some embodiments, the composition as defined herein is nonpsychoactive and does not exhibit any psycho-effect on the subject.

[0055] Other components that may be found in cannabis and that may be found in isolates or extracts thereof include, but are not limited to: terpenoids, hydrocarbons, nitrogen-containing compounds, carbohydrates, flavonoids, fatty acids, noncannabinoid phenols, alcohols, aldehydes, ketones, acids, esters and lactones.

ii) Absorbable Material

[0056] In certain embodiments, the absorbable material comprises a glycosaminoglycan. The absorbable material may comprise two or more different glycosaminoglycans (GAG). Members of the GAG family vary in the type of hexosamine, hexose or hexuronic acid unit they contain, such as, e.g., glucuronic acid, iduronic acid, galactose, galactosamine, glucosamine, and may also vary in the geometry of the glycosidic linkage. Non-limiting examples of glycosaminoglycans include chondroitin sulfate, dermatan sulfate, keratan sulfate, and hyaluronan. Non-limiting examples of an acceptable salt of a glycosaminoglycans includes sodium salts, potassium salts, magnesium salts, calcium salts, and combinations thereof.

[0057] In some implementations of these embodiments, the glycosaminoglycan is hyaluronic acid (HA) (sodium hyaluronate). In some instances, the HA is cross-linked HA. In some other instances, HA is non-cross-linked HA. The molecular weight of HA is proportional to the number of repeating disaccharides in the HA molecule, and is a determiningfactor in its rate of metabolization following oral administration, and topical absorption. More specificaly, High molecuar weight HA is metabolized slowly, compared to lower molecular weight HA, following consumption, and low molecular weight HA is absorbed faster through the skin, than high molecular weight HA. High molecular weight HA has a molecular weight of at least about 1.0 million Daltons (lxlO⁶ Da or 1

MDa) to about 4.0 MDa, whereas low molecular weight HA has a molecular weight of less than about 1.0 MDa. In some instances, the HA used in the compositions of the present technology has an average molecular weight of between about 5 kilo Daltons (kDa) and about 4.0 million Daltons (MDa), between about 5 kDa and about 1.5 MDa, between about 8 kDa and about 1.5 MDa, between about 80 kDa and about 1.5 MDa, between about 5 kDa and about 110 kDa, between about 8 kDa and about 110 kDa, between about 80 kDa and about 110 kDa, between about 5 kDa and about 1.0 MDa, between about 8 kDa and about 1.0 MDa, between about 100 kDa and about 1.5 MDa, or between about 1.0 MDa and about 1.5 MDa, or below about 110 kDa, or above about 80 kDa, or below about 1.5 MDa.

[0058] The hyaluronic acid may be about 0.01% to about 2%, about 0.01% to about 1%, about 0.1% to about 2%, about 2% to about 30%, about 2% to about 25%, about 2% to about 20%, about 2% to about 15%, about 2% to about 10%, about 2% to about 5%, 4% to about 30%, about 4% to about 25%, about 4% to about 20%, about 4% to about 15%, about 4% to about 10%, about 4% to about 5%, of the compositions of the present technology.

[0059] In one embodiment, the compositions of the present technology comprise a cannabinoid:HA ratio ranging from about 1:1 to about 1:100, or ranging from about 1:1 to about 100:1, or ranging from about 1:1 to about 1:75, or ranging from about 1:1 to about 75:1, or ranging from about 1:1 to about 1:50, or ranging from about 1:1 to about 50:1, or ranging from about 1:1 to about 1:25, or ranging from about 1:1 to about 25:1, or ranging from about 1:1 to about 1:10, or ranging from about 1:1 to about 10:1, or ranging from about 1:1 to about 1:9, or ranging from about 1:1 to about 9:1, or ranging from about 1:1 to about 1:8, or ranging from about 1:1 to about 8:1, or ranging from about 1:1 to about 1:7, or ranging from about 1:1 to about 7:1, or ranging from about 1:1 to about 1:6, or ranging from about 1:1 to about 6:1, or ranging from about 1:1 to about 1:5, or ranging from about 1:1 to about 5:1, or ranging from about 1:1 to about 1:4, or ranging from about 1:1 to about 4:1, or ranging from about 1:1 to about 1:3, or ranging from about 1:1 to about 3:1, or ranging from about 1:1 to about 1:2, or ranging from about 1:1 to about 2:1, or ranging from about 1:1 to more than 1:100, or ranging from about 1:1 to more than about 100:1.

[0060] In some embodiments, the hyaluronic acid is substantially stable at room temperature for, e.g., about 3 months, about 6 months, about 9 months, about 12 months, about 15 months, about 18 months, about 21 months, about 24 months, about 27 months, about 30 months, about 33 months, or about 36 months.

ili) Additional Optional Ingredients

[0061] In some embodiments, the compositions of the present technology are liquid compositions comprising water as the carrier. Suitable amounts of water can be from about 0.1% by weight of the composition to about 99.9% by weight of the composition. More typically, the amount of water can be from about 20% by weight of the composition to about 99.9% by weight of the composition, from about 30% by weight of the composition to about 99.9% by weight of the composition, from about 40% by weight of the composition to about 99.9% by weight of the composition, from about 50% by weight of the composition to about 99.9% by weight of the composition, or from about 60% by weight of the composition to about 99.9% by weight of the composition.

[0062] In some embodiments, the compositions of the present technology may further include additional ingredients and optional ingredients such as, but not limited to, the ones defined hoe below in this section of the disclosure.

[0063] In another embodiment, the compositions of the present technology may include a hydrophobic carrier. Suitable hydrophobic carriers can be, for example, natural oils, synthetic oils and combinations thereof.

[0064] In some embodiments, the compositions of the present technology may include at least one botanical extract . Examples of botanical extracts that may be used in the methods of the present technology include, but are not limited to: angelica extract, avocado extract, tasmannia lanceolata extract, wild yam extract, boswellia spp. extract, fenugreek extract, harpagophytum spp. extract, hydrangea extract, althea extract, arnica spp. extract, aloe extract, apricot extract, apricot core extract, ginkgo extract, fennel extract, turmeric extract, oolong tea extract, rose fruit extract, echinacea leaf extract, Scutellaria root extract, phellodendron bark extract, goldthread extract, barley extract, hypericum extract, white nettle extract, watercress extract, orange extract, sea salt, seaweed extract, hydrolyzed elastin, hydrolyzed wheat powder, hydrolyzed silk, chamomile extract, carrot extract, artemisia capillaris extract, glycyrrhiza extract, sabdariffa extract, pyracantha fortuneana fruit extract, cinchona extract, cucumber extract, guanosine, gardenia extract, sasa albo-marginata extract, sophora root extract, walnut extract, grapefruit extract, clematis extract, chlorella extract, mulberry bark extract, gentian extract, black tea extract, yeast extract, burdock extract, fermented rice bran extract, rice germ oil, comfrey extract, collagen, cowberry extract, asiasarum root extract, bupleurum falcatum root extract, umbilical cord extract, salvia extract, saponaria extract, bamboo grass extract, Crataegus extract, zanthoxylum fruit extract, shiitake mushroom extract, rehmannia root extract, lithospermum root extract, perilla extract, linden extract, filipendula extract, peony root extract, calamus rhizome extract, birch extract, horsetail extract, ivy extract, hawthorn extract, sambucus nigra extract, yarrow extract, peppermint extract, sage extract, mallow extract, cnidium rhizome extract, swertia herb extract, soy extract, jujube extract, wild thyme extract, green tea extract, clove extract, cogon extract, citrus unshiu peel extract, angelica root extract, calendula extract, peach seed extract, bitter orange extract, houttuynia extract, tomato extract, natto extract, ginseng extract, garlic extract, wild rose extract, hibiscus sabdariffa flower extract, ophiopogon tuber extract, parsley extract, honey, witch hazel extract, pellitory extract, isodonis extract, matricaria extract, loquat extract, coltsfoot extract, butterbur scape extract, Poria cocos extract, butcher bloom extract, grape extract, propolis, luffa extract, safflower extract, peppermint extract, linden extract, peony extract, hop extract, pine extract, horse chestnut extract, skunk cabbage extract, sapindaceae extract, balm mint extract, peach extract, cornflower extract, eucalyptus extract, saxifrage extract, coix seed extract, mugwort extract, lavender extract, apple extract, lettuce extract, lemon extract, Chinese milk vetch extract, rose extract, rosemary extract, Roman and/or german chamomile extract, royal jelly extract, ginkgo biloba extract, harpogophytum extract, arthrospira platensis (spirulina) extract, and punica granatum extract.

[0065] The topical compositions described herein can further include a skin penetrating enhancer or a mixture of skin penetration enhancers. A skin penetrating enhancer allows for the composition to pass through the epidermal layer and the dermal layer of the skin to reach the adipose tissue that underlies the skin wherein adipocytes are increased in number and/or size. This may be accomplished by a number of different mechanisms including, for example, by extracting lipids from the stratum comeum, increasing the partitioning of the active ingredients into the skin, and disrupting the lipid bilayer of the stratum comeum, thus rendering the stratum comeum structure more fluid and increasing the ability of the composition including the cannabinoids to diffuse through the stratum comeum. Suitable skin penetrating enhancers can be, for example, sulfoxides, alcohols, fatty acids, fatty acid esters, polyols, amides, surfactants, terpenes, alkanones, and organic acids, among others. Specific examples of suitable sulfoxides include dimethylsulfoxide (DMSO) and decylmethylsulfoxide, among others. Suitable alcohols include alkanols such as ethanol, propanol, butanol, pentanol, hexanol, octanol, n-octanol, nonanol, decanol, 2-butanol, 2-pentanol, and benzyl alcohol; fatty alcohols, such as caprylic alcohol, decyl alcohol, lauryl alcohol, 2-lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, oleyl alcohol, linoleyl alcohol, and linolenyl alcohol; and isopropyl alcohol. Examples of suitable fatty acids include linear fatty acids such as valeric acid, heptanoic acid, pelagonic acid, caproic acid, capric acid, lauric acid, myristic acid, stearic acid, oleic acid, and caprylic acid; and branched fatty acids, such as isovaleric acid, neopentanoic acid, neoheptanoic acid, neononanoic acid, trimethyl hexanoic acid, neodecanoic add, and isostearic acid. Examples of suitable fatty acid esters include aliphatic fatty acid esters such as isopropyl n-butyrate, isopropyl n-hexanoate, isopropyl n-decanoate, isopropyl myristate, isopropyl palmitate, and octyldodecyl myristate; alkyl fatty acid esters such as ethyl acetate, butyl acetate, methyl acetate, methylvalerate, methylpropionate, diethyl sebacate, and ethyl oleate; and diisopropyl adipate and dimethyl isosorbide. Examples of suitable polyols include propylene glycol, butylene glycol, polyethylene glycol, ethylene glycol, diethylene glycol, triethylene glycol, dipropylene glycol, ethoxydiglycol, pentylene glycol, glycerol, propanediol, butanediol, pentanediol, hexanetriol, and glycerin. Examples of suitable amides include urea, dimethylacetamide, diethyltoluamide, dimethylformamide (DMF), dimethyloctamide, dimethyldecamide, biodegradable cyclic urea (e.g., l-alkyl-4-imidazoline-2-one), pyrrolidone derivatives, biodegradable pyrrolidone derivatives (e.g., fatty acid esters of N-(2-hydroxyethyl)-2-pyrrolidone), cyclic amides, hexamethylenelauramide and its derivatives, diethanolamine, and triethanolamine. Examples of pyrrolidone derivatives include 1- methyl-2-pyrrolidone, 2-pyrrolidone, l-lauryl-2-pyrrolidone, l-methyl-4-carboxy-2-pyrrolidone, 1- hexyl-4-carboxy-2-pyrrolidone, l-lauryl-4-carboxy-2-pyrrolidone, l-methyl-4-methoxycarbonyl-2- pyrrolidone, 1 -hexyl-4-methoxycarbonyl-2-pyrrolidone, 1 -lauryl-4-methoxycarbonyl-2-pyrrolidone, N-cyclohexylpyrrolidone, N-dimethylaminopropylpynOlidone, N-cocoalkypyrrolidone, N- tallowalkylpyrrolidone, and N-methylpyrrolidone. Examples of cyclic amides include 1- dodecylazacycloheptane-2-one (e.g., Azone), 1 -geranylazacycloheptan-2-one, 1- famesylazacycloheptan-2-one, 1 -geranylgeranylazacycloheptan-2-one, H3,7- dimethyloctyl)azacycloheptan-2-one, 1 -(3 ,7, 11 -trimethyldodecyl)azacyclohaptane-2-one, 1- geranylazacyclohexane-2-one, l-geranylazacyclopentan-2,5-dione, and l-famesylazacyclopentan-2- one.

[0066] The compositions of the present technology may include from about 0.001% (by weight of the composition) to about 25% (by weight of the composition) of a skin penetration enhancer, including from about 0.1% (by weight of the composition) to about 15% (by weight of the composition) of a skin penetration enhancer, and including from about 1% (by weight of the composition) to about 10% (by weight of the composition) of a skin penetration enhancer.

[0067] Optionally, the compositions may be formulated with a polar co-solvent to further increase the permeability of the composition into the skin. Preferably, the polar co-solvent is fully miscible in the composition, and has a high affinity for the intercellular spaces in the stratum comeum. Without wishing to be bound by any particular theory, it is believed that polar co-solvents with such characteristics are driven by osmosis into the intercellular spaces in the stratum comeum, causing the stratum comeum to swell. In such a swollen state, the intercellular spaces are more liquid-like and disordered, which enables the composition to more easily diffuse through the stratum comeum. Examples of suitable polar co-solvents for inclusion in the compositions of the present technology include glycerin, propanediol, ethanol, propylene glycol, butanol, isopropanol, propanol, dimethyl isosorbide, butylene glycol, polyethylene glycol, dipropylene glycol, ethoxydiglycol, pentylene glycol, and combinations thereof.

[0068] The compositions of the present technology may include from about 0.001% (by weight of the composition) to about 99% (by weight of the composition) of a polar co-solvent, including from about 0.01% (by weight of the composition) to about 75% (by weight of the composition) of a polar co-solvent, including from about 0.1% (by weight of the composition) to about 50% (by weight of the composition) of a polar co-solvent, including from about 1% (by weight of the composition) to about 25% (by weight of the composition) of a polar co-solvent, including from about 2% (by weight of the composition) to about 15% (by weight of the composition) of a polar cosolvent, and including from about 2.5% (by weight of the composition) to about 10% (by weight of the composition) of a polar co-solvent.

[0069] The composition can further include other known collagen, elastin, and extracellular matrix-stimulating ingredients. Collagen is a protein found in the connective tissue of the skin and other tissues of the body. Suitable collagen enhancers can be, for example, vitamins such as ascorbic acid and derivatives thereof, peptides such as palmitoyl tripeptide-5, botanical extracts such as pomegranate or mushroom, and minerals such as hematite. Elastin is a protein found in the connective tissue of the skin and other tissues of the body. Suitable elastin enhancers can be, for example, vitamins such as ascorbic acid and derivatives thereof, peptides such palmitoyl hexapeptide-12, botanical extracts such as kudzu, horsetail, rice, dill and rosemary, and minerals such as zinc and copper.

[0070] The compositions can further include a vasodilator. Vasodilators can increase the blood flow within the skin. Suitable vasodilators can be, for example, glyceryl trinitrate, resveratrol, caffeine, ginger extract, ginseng and other botanical extracts such as, for example, hawthorn, mint, ivy, coffee and tea.

[0071] The compositions can further include a skin soothing agent. As used herein,“skin soothing agent” refers to compounds that reduce or prevent skin irritation. Skin irritation can result from loss of moisture, a change in pH, sweat, contact dermatitis from perfumes, powders, laundry detergent from clothing, and other compounds. Skin soothing agents can reduce irritation by neutralizing an irritant, down-regulating inflammatory cascades in the skin, and/or providing a protective layer on the skin. Suitable skin soothing agents can be, for example, botanical extracts such as calendula, chamomile, aloe, comfrey, coneflower, allantoin, bisabolol, panthenol, beta- glucan, colloidal oatmeal, or the like.

[0072] The compositions can further include a humectant. Humectants can elevate the hydration of the skin, in particular the epidermis and the dermis. Suitable humectants can be, for example, glycerol, glycerin, lactic acid, urea, aloe vera, betaine, hyaluronic acid, propanediol, propylene glycol, butylene glycol, and combinations thereof.

[0073] The compositions can further include an emulsifier, and in particular, an emulsifier that creates liquid crystalline networks or liposomal networks. Suitable non-limiting exemplary emulsifiers include, for example, OLIVEM^® 1000 (INCI: Cetearyl Olivate (and) Sorbitan Olivate; commercially available from HallStar Company (Chicago, M.)), Arlacel^® LC (INCI: Sorbitan Stearate (and) Sorbityl Laurate; commercially available from Croda (Edison, N.J.), CRYSTALCAST^® MM (INCI: Beta Sitosterol (and) Sucrose Stearate (and) Sucrose Distearate (and) Cetyl Alcohol (and) Stearyl Alcohol; commercially available from MMP Inc. (South Plainfield, N.J.), UNIOX CRISTAL^® (INCI: Cetearyl Alcohol (and) Polysoibate 60 (and) Polysoibate 20 (and) Polysorbate 80 (and) Cetearyl Glucoside; commercially available from Chemyunion (Sao Paulo, Brazil). Other suitable emulsifiers include lecithin, hydrogenated lecithin, cetyl alcohol, EComulse, glyceryl stearate, lanolin, olivem, polawax, wax, stearic acid, lysolecithin, phosphatidylcholine, phospholipids, and combinations thereof.

[0074] The compositions can further include a preservative to preserve the stability. Preservatives can also prevent the growth of microbial organisms in the compositions. Suitable preservatives may be selected from: methylparabens, ethylparabens, propylparabens, butylparabens, sorbic acid, acetic acid, propionic acid, sulfites, nitrites, sodium sorbate, potassium sorbate, calcium sorbate, benzoic acid, sodium benzonate, potassium benzonate, calcium benzonate, sodium metabisulfite, piropylene glycol, benzaldehyde, butylated hydroxytoluene, butylated hydroxyanisole, formaldehyde donors, botanical extracts, monoglyceride, phenol, mercury components and any combination thereof.

[0075] The compositions of the piresent technology may include oils and butters, such as but not limited to: apricot oil, argan oil, avocado oil, baobab oil, black cumin seed oil, borage oil, calendula oil, camelina oil, caprylis oil, castor oil, cocoa butter, coconut oil, evening primrose oil, grapeseed oil, green tea oil, hazelnut oil, hemp seed oil, jojoba oil, kokum butter, macadamia oil, mango butter, shea butter, neem oil, olive oil, p)alm oil, plantain oil, prickly p>ear oil, red p)alm fruit oil, rosehip oil, sea buckthorn oil, sesame oil, St. John's wort oil, sunflower seed oil, sweet almond oil, tamanu oil, and wheat germ oil, an any combinations thereof.

[0076] The compositions of the present technology may include waxes, such as but not limited to: beeswax, candelilla wax, camauba wax, castor wax, cetyl alcohol wax, soya wax, glyceryl stearate wax, soy wax, and any combinations thereof.

[0077] The compositions can further include a pH adjuster to control/maintain the pH of the composition within the range of skin pH. A suitable pH range of the composition can be from about 3.5 to about 6 or from about 4 to about 7.

[0078] The compositions can further include fragrances, scents, dyes, surfactants, rheology modifiers, film formers and other components known to be useful in personal care formulations.

[0079] Suitable surfactants include anionic surfactants, amphoteric surfactants, cationic surfactants, zwitterionic surfactants, non-ionic surfactants, and combinations thereof. Suitable anionic surfactants include, for example, alkyl sulfates, alkyl ether sulfates, alkyl aryl sulfonates, alpha-olefin sulfonates, alkali metal or ammonium salts of alkyl sulfates, alkali metal or ammonium salts of alkyl ether sulfates, alkyl phosphates, silicone phosphates, alkyl glyceryl sulfonates, alkyl sulfosuccinates, alkyl taurates, acyl taurates, alkyl sarcosinates, acyl sarcosinates, sulfoacetates, alkyl phosphate esters, mono alkyl succinates, monoalkyl maleates, sulphoacetates, acyl isethionates, alkyl carboxylates, phosphate esters, sulphosuccinates (e.g., sodium dioctylsulphosuccinate), and combinations thereof. Specific examples of anionic surfactants include sodium lauryl sulphate, sodium lauryl ether sulphate, ammonium lauryl sulphosuccinate, ammonium lauryl sulphate, ammonium lauryl ether sulphate, sodium dodecylbenzene sulphonate, triethanolamine dodecylbenzene sulphonate, sodium cocoyl isethionate, sodium lauroyl isethionate, sodium N-lauryl sarcosinate, and combinations thereof. Suitable cationic surfactants include, for example, alkyl ammonium salts, polymeric ammonium salts, alkyl pyridinium salts, aryl ammonium salts, alkyl aryl ammonium salts, silicone quaternary ammonium compounds, and combinations thereof. Specific examples of cationic surfactants include behenyltrimonium chloride, stearlkonium chloride, distearalkonium chloride, chlorohexidine diglutamate, polyhexamethylene biguanide (PHMB), cetyl pyridinium chloride, benzammonium chloride, benzalkonium chloride, and combinations thereof. Suitable amphoteric surfactants include, for example, betaines, alkylamido betaines, sulfobetaines, N -alkyl betaines, sultaines, amphoacetates, amophodiacetates, imidazoline carboxylates, sarcosinates, acylamphoglycinates, such as cocamphocarboxyglycinates and acylamphopropionates, and combinations thereof. Specific examples of amphoteric surfactants include cocamidopropyl betaine, lauramidopropyl betaine, meadowfoamamidopropyl betaine, sodium cocoyl sarcosinate, sodium cocamphoacetate, disodium cocoamphodiacetate, ammonium cocoyl sarcosinate, sodium cocoamphopropionate, and combinations thereof. Suitable zwitterionic surfactants include, for example, alkyl amine oxides, silicone amine oxides, and combinations thereof. Specific examples of suitable zwitterionic surfactants include, for example, 4-[N,N-di(2-hydroxyethyl)-N- octadecylammonio]-butane-l-carboxylate, S--[S-3-hydroxypropyl-S-hexadecylsulfonio]-3- hydroxypentane-l-sulfate, 3-[P,P-diethyl-P-3,6,9-trioxatetradexopcylphosphonio]-2 hydroxypropane-1- phosphate, 3-[N,N-dipropyl-N-3-dodecoxy-2-hydroxypropylammonio]- propane-1- phosphonate, 3-(N,N-dimethyl-N-hexadecylammonio)propane-l-sulfomte, 3-(N,N- dimethyl-N-hexadecylammonio)-2-hydroxypropane-l-sulfonate, 4-[N,N-di(2-hydroxyethyl)-N-(2- hydroxydodecyl)ammonio]-butane-l -carboxylate, 3-[S-ethyl-S-(3-dodecoxy-2- hydroxypropyl)sulfonio]-propane-l-phospliate- , 3- [P J’-dimethyl-P-dodecylphosphonio] -propane- 1 - phosphorate, 5-[N,N-di(3-hydroxypropyl)-N-hexadecylammonio]-2-hydroxy-pentane-l-sulfat- e, and combinations thereof. Suitable non-ionic surfactants include, for example, mono- and di- alkanolamides such as, for example, cocamide MEA and cocamide DEA, amine oxides, alkyl polyglucosides, ethoxylated silicones, ethoxylated alcohols, ethoxylated carboxylic acids, ethoxylaled amines, ethoxylated amides, ethoxylated alkylolamides, ethoxylated alkylphenols, ethoxylated glyceryl esters, ethoxylated sorbitan esters, ethoxylated phosphate esters, glycol stearate, glyceryl stearate, and combinations thereof. It will be recognized by one skilled in the art that many of the nonionic surfactants described herein may act to improve the foaming properties of the cleansing composition of the multi-product care system, and may provide a more compact, reduced bubble size or creamy foam.

[0080] The compositions of the present technology may also include a thickener, which acts to thicken or increase the viscosity of the compositions. For example, the thickener may be a cellulosic thickener or gum. Examples of suitable cellulosic or gum thickeners include xanthan gum, agar, alginates, carrageenan, furcellaran, guar, cationic guar, gum arabic, gum tragacanth, karaya gum, locust bean gum, dextran, starch, modified starches, gellan gum, carboxymethylcellulose, hydroxypropylcellulose, hydroyethylcellulose, propylene glycol alginate, hydroxypropyl guar, amylopectin, cellulose gum, chitosan, modified chitosan, hydroxypropyl methylcellulose, microcrystalline cellulose, silica, firmed silica, colloidal silica, dehydroxanthan gum, non-acrylic based carbomers, and combinations thereof. Alternately or in addition, the thickener may be an acrylic based polymer. Non-limiting examples of suitable acrylic based polymer thickeners include acrylates/C 10-C30 alkyl acrylate crosspolymers, certain carbomers, acrylates copolymers, aminoacrylates copolymers, and combinations thereof. Examples of commercially available acrylic based polymer thickeners include Structure^® Plus (Akzo Nobel, Pasadena, Calif.), which is an acrylates/aminoacrylates/C 10-30 alkyl PEG-20 itaconate copolymer, Carbopol^® Aqua SF-1 Polymer (Lubrizol Advanced Materials, Cleveland, Ohio), which is an acrylates copolymer, PEMULEN^® TR- 1 and TR-2 and Carbopol^® ETD 2020 (available from Lubrizol Advanced Materials), which are acrylates/C 10-30 alkyl acrylates crosspolymers, and the Carbopol^® Ultrez series of polymers (available from Lubrizol Advanced Materials), which are carbomers.

[0081] The compositions of the present technology may further comprises a finishing agent that typically delivers moisturization, skin protection, or a moisture-barrier for sealing in moisture to the user. Specifically, the finishing agent can be any moisturizing agent, skin protectant, and/or moisture-barrier enhancing agent known in the art. Additionally, the finishing agent may be capable of providing aesthetic benefits such as skin smoothing or a powdery feel. Examples of additional suitable finishing agents include skin conditioning agents (e.g., pH adjusting agents, moisturizers, skin conditioners, exfoliation agents, shaving lubricants, skin-firming agents, anti-callous agents, anti-acne agents, anti-aging agents, anti-wrinkle agents, anti-dandruff agents, wound care agents, skin lipids, enzymes, scar care agents, humectants, powders, botanical extracts, and drugs), fragrances, botanical extracts, powders, and combinations thereof.

[0082] In some embodiments, the composition additionally comprises at least one carrier or excipient selected from a group consisting of diluents, antiadherents, binders, coatings, disintegrants, surfactants, dissolving agents, solubilising agents, bioadhesive agents, polysaccharides, polymers, copolymers, fast dissolving tablet (FDT) type excipient, bioavailability enhancing agent, Thin Film type excipient, PharmFilm type excipient, mucoadhesive type excipient, acidifying agents, probiotic agents, protective agents, antioxidants, effervescent excipient, dispersing agents flavours, colours, lubricants, glidants, sorbents, preservatives, sweeteners, and any combination thereof.

[0083] In some embodiments, the composition of the present technology may be administered in combination with at least one pharmaceutical agent. Such a pharmaceutical agent may be any medication having a clinical effect on a human patient, and especially preferred are pharmaceutical compositions directed towards medical conditions which may also benefit from administration of cannabinoids, such as in pain management, nausea, appetite stimulation and the like.

[0084] In some embodiments, the composition of the present technology may be administered in combination with at least one nutraceutical agent, such as any plant-derived nutrients, synthetically derived nutrients, dietary supplements or herbal products.

[0085] It is further within the scope to provide the composition as defined in any of the above, wherein the composition is administered in a manna· selected from a group consisting of: intranasal, transdermal, intravenous, oral, and any combination thereof.

[0086] In some embodiments, the compositions of the present technology are formulated for oral administration (e.g., ingestion). In these embodiments, the composition is edible or drinkable. In some implementations of these embodiments, the compositions of the present technology are formulated into food or into beverages, wherein the formulations comprises any components suitable for consumption. In some instances wherein the compositions of the present technology are formulated into beverages, the bevoages are non-alcoholic beverages. In some other instances wherein the compositions of the present technology are formulated into beverages, the beverages are alcoholic beverages.

[0087] In some embodiments, the compositions of the present technology are formulated for intranasal administration. In these embodiments, the composition may be administered as a nasal spray, nasal drop, suspension, gel, ointment, cream or powder. The administration of the nasal composition may also take place using a nasal tampon or nasal sponge, containing the compositions of the present technology, or any other method suitable for administration through the nasal muscosa. The form of dosage for intranasal administration may include solutions, suspensions or emulsions of the composition. The dosage forms may be sterilized, as required. The dosage forms may also contain adjuvants such as preservatives, stabilizers, emulsifiers or suspending agents, wetting agents, salts for varying the osmotic pressure or buffers, as required,

iv) Methods of Use

[0088] Without wishing to be bound by theory, it is believed that, in some embodiments, the compositions of the present technology facilitate delivery of the cannabinoids into the layers of the skin. In particular, it is believed that the absorbable material, present in the composition, facilitates absorption of the cannabinoids by the skin. The absorbable material therefore acts as a delivery vehicle for the cannabinoids to the various layers of the skin.

[0089] Without wishing to be bound by theory, it is also believed that, in some embodiments, the compositions of the present technology enable oral delivery of cannabinoids. In certain embodiments, it is believed that the absorbable material, present in the composition, may allow for a more efficient metabolization. The absorbable material therefore may act to increase the bioavailability of cannabinoids following consumption.

[0090] As such, in some embodiments, the present technology is directed to a method for reducing the signs of skin aging in an individual in need thereof. The method includes topically applying a composition comprising at least one cannabinoid and at least one absorbable material to a subject. As used herein, a“subject in need thereon” refers to a subject having skin showing visible signs of aging such as, for example, wrinkles, fine lines, thinning skin, sagging skin, skin dryness, skin itchiness, skin fragility, loss of skin elasticity, and combinations thereof.

[0091] Furthermore, without wishing to be bound by theory, it is believed that, in some embodiments, the compositions of the present technology facilitate delivery of the cannabinoids into the layers of the skin. In particular, in certain embodiments, it is believed that the absorbable material, present in the composition, facilitates absorption of the cannabinoids by the skin. The absorbable material therefore acts as a delivery vehicle for the cannabinoids to the various layers of the skin.

[0092] As such, in some embodiments, the methods disclosed herein are directed to a subset of the general population such that, in these embodiments, not all of the general population may benefit from the methods. Based on the foregoing, because some of the method embodiments of the present technology are directed to specific subsets or subclasses of identified subjects (that is, the subset or subclass of subject“in need” of assistance in addressing one or more specific conditions noted herein), not all subjects will fall within the subset or subclass of subjects as described herein.

[0093] The compositions of the present technology can be applied to the target skin region

(e.g., face, neck, ears, scalp, arms, hands, legs, feet, etc.) by any suitable delivery vehicle. For example, the composition can be applied as a lotion, as a wash, as a gel, as a salve, as an ointment, as a cream, as a solid stick, as a paste, as a balm, as a serum and as a foam. Additionally, the composition can be applied with a wipe, with mitts and gloves, using an aerosol dispenser, using a pump spray, using a trigger spray, using a squeeze bottle, and using a mask (having a composition of the present technology applied on a surface thereof).

[0094] The compositions of the present technology can be applied daily, every other day, every couple of days, every week, every month, and every year, as desired. The compositions can be applied multiple times pa- day (e.g., at least twice, at least three times, at least four times, etc.), multiple times per week and/or multiple times per month.

[0095] In some embodiments, the compositions of the present disclosure can be used with additional skin care compositions as part of a skin care regimen. For example, in facial treatment and care, users typically use multiple products for cleansing, toning, and treating the skin of the face. Accordingly, the first product comprises a first composition typically capable of providing a first benefit to a user, and the second product comprises a second composition typically capable of providing a second benefit to a user. In the present disclosure, it should be understood that at least one of the products of the regimen includes the compositions of the present technology, thereby at least providing the benefit of reducing signs of skin aging.

[0096] In one embodiment, the compositions of the present technology are formulated and/or prepared for topical administration or topical application. The compositions suitable for topical application may be in the form of, for example, a cream, a lotion, a cosmetic serum, a solution, a gel, an ointment, a paste, a bioadhesive, a powder or the like. They may also be prepared so as to comprise nanosized materials such as liposomes, micelles, nanoparticles, nanoemulsions , polymeric suspensions, microparticles and/or microspheres (or any other encapsulation systems) according to known methods and techniques in the art. Nanosized materials are often used as skin penetrating enhancers, as they are reported to enhance skin penetration compared to larger particles, and are more likely to penetrate the stratum comeum.

[0097] In some embodiments, the nanosized material may comprise HA polymeric micelles. HA is a biodegradable polymer, and thereby minizes the risk of non-biodegradable foreign particle accumulation in the body following penetration in the skin, when used as polymer in the formation of nanosized materials. Furthermore, HA is naturally present in both the epidermis and dermis, and constitutes a large fraction of the extracellular matrix of the skin. As such, HA is considered to represent an ideal candidate material in topical drug delivery, especially in skin drug delivery. The HA polymeric micelles may be formed by acylated derivates of HA with short and medium chain length. The HA polymeric micelles may be further loaded with other active substances, in accordance with their use, by known methods and techniques in the art.

[0098] In some implementations of this embodiment, the compositions are aqueous (i.e., comprise water) or are substantially non-aqueous (i.e., comprise trace amount of water) or are non- aqueous (i.e., do not comprise water). The compositions may also optionally be used in combination with an occlusive over layer so that moisture evaporating from the body surface is maintained within the composition upon application to the body surface and thereafter.

[0099] According to one implementation, the compositions are prepared as creams. Creams, as well known in the art, are viscous liquids or semi-solid emulsions that are divided into two types: oil-in-water (O/W) creams which are composed of small droplets of oil disposed in a continuous phase, and water-in-oil (W/O) creams which are composed of small droplets of water dispersed in a continuous oily phase. Oil-in-water creams are less greasy and more easily washed off using water. Water-in-oil creams are typically more moisturizing as they provide an oily barrier which reduces water loss from the stratum comeum, the outermost layo of the skin.

[00100] According to another implementation, the compositions are prepared as lotion. Lotions are preparations to be applied to the skin surface without friction, and are typically liquid or semi liquid preparations in which solid particles, including the active agent, are present in a water or alcohol base. Lotions are usually suspensions of solids.

[00101] According to another implementation, the compositions are prepared as pastes. Pastes are semisolid dosage forms in which the active agent is suspended in a suitable base. Depending on the nature of the base, pastes are divided between fatty pastes or those made from a single-phase aqueous gel.

[00102] According to another implementation, the compositions are prepared as ointments. Ointments are semisolid preparations that are typically based on petrolatum or other petroleum derivatives. The specific ointment base to be used, as will be appreciated by those skilled in the art, is one that will provide for optimum treatment of the skin, for improving appearance of the skin.

[00103] According to another implementation, the compositions are prepared as gels. As will be appreciated by those working in the field of formulation, gels are semisolid, suspension-type systems. Single-phase gels contain organic macromolecules distributed substantially uniformly throughout the carrier liquid, which is typically aqueous, but also, preferably, contain an alcohol and, optionally, oil.

[00104] Examples of skin areas that can be treated and/or that may be applied with the compositions of the present technology include but are not limited to, the skin of the face (e.g., forehead, cheeks, eyelids, contour of the eyes, jaw line, chin, nose, ears, etc.), the skin of the neck, the skin of upper torso, the skin of the arms, skin of the legs, skin of the feet, skin of the hands, skin of the elbows, skin of the knees, etc. The compositions of the present technology may also be applied to other integuments of a subject such as on hair and on nail.

[00105] The methods of the present technology generally comprise applying an effective amount of the compositions defined herein onto an area of an integument of a subject in need thereof. The expression“effective amount”, as used herein, unless otherwise specified, refers to an amount effective and for periods of time necessary, to achieve the desired cosmetic result. An effective amount of the skin stem cells activator agent noted herein may vary according to factors such as, the desired cosmetic effect, the desired appearance of the skin, age and sex of the subject, skin health, skin damage, dryness of the skin, overall health of the subject, etc. The number of applications of the compositions on the skin pa- day may be adjusted to provide the optimum response. An effective amount is also one in which any detrimental effects are outweighed by the beneficial effects.

[00106] As used herein, the term“treated” designates an area of an integument of a subject (e.g. skin, nails, hair) onto which the compositions as defined herein have been applied. Before being “treated” these areas are generally in need of skin care and/or in need of appearance improvement, an increase in firmness, an increase in elasticity, an increase in hydration, a decrease in wrinkle depth, and/or wherein the epidermis is in need of activation, rejuvenation, vitalization, growth, repair, and/or regeneration.

[00107] In particular, the present invention provides methods that have the potential of improving appearance of the skin, skin firmness, skin elasticity, skin moisture; the potential of reducing wrinkle depth, of promoting growth, repair, vitalization, regeneration and/or survival of the epidermis and/or epidermal stem cells and potentially the dermis and/or the dermal stem cells.

[00108] In some embodiments, the compositions and methods of the present disclosure promote skin rejuvenation. In certain other embodiments, the compositions and methods of the present disclosure may reduce, diminish, retard or even reverse one or more signs of skin aging including, but not limited to, appearance of fine lines or wrinkles, thin and transparent skin, loss of underlying fat (leading to hollowed cheeks and eye sockets as well as noticeable loss of firmness on the hands and neck), bone loss (such that bones shrink away from the skin due to bone loss, which causes sagging skin), dry skin (which might itch), inability to sweat sufficiently to cool the skin, unwanted facial hair, freckles, age spots, spider veins, rough and leathery skin, fine wrinkles that disappear when stretched, loose skin, or a blotchy complexion. In certain embodiments, the compositions and methods of the present disclosure may induce a reduction in pore size, enhance sculpturing of skin subsections, and/or enhance skin translucence. [00109] In some embodiments, the compositions of the present technology are used in a method for preventing and/or treating acne. The method comprising an effective amount of a composition as defined herein to an area of a subject afflicted with acne. As used herein,“acne” means a disorder of the skin caused by inflammation of skin glands or hair follicles. The compositions and methods of the disclosure can be used to treat acne at early pre-emergent stages or lata- stages where lesions from acne are visible. Mild, moderate and severe acne can be treated with embodiments of the compositions and methods. Early pre-emergent stages of acne usually begin with an excessive secretion of sebum or dermal oil from the sebaceous glands located in the pilosebaceous apparatus. Sebum reaches the skin surface through the duct of the hair follicle. The presence of excessive amounts of sebum in the duct and on the skin tends to obstruct or stagnate the normal flow of sebum from the follicular duct, thus producing a thickening and solidification of the sebum to create a solid plug known as a comedone. In the normal sequence of developing acne, hyperkeratinazation of the follicular opening is stimulated, thus completing blocking of the duct. The usual results are papules, pustules, or cysts, often contaminated with bacteria, which cause secondary infections. Acne is characterized particularly by the presence of comedones, inflammatory papules, or cysts. The appearance of acne may range from slight skin irritation to pitting and even the development of disfiguring scars. Accordingly, the compositions and methods of the present disclosure can be used to treat one or more of skin irritation, pitting, development of scars, comedones, inflammatory papules, cysts, hyperkeratinazation, and thickening and hardening of sebum associated with acne. The compositions and methods of the present disclosure may be used to treat various types of acne.

Some types of acne include, for example, acne vulgaris, cystic acne, acne atrophica, bromide acne, chlorine acne, acne conglobata, acne cosmetica, acne detergicans, epidemic acne, acne estivalis, acne fulminans, halogen acne, acne indurata, iodide acne, acne keloid, acne mechanica, acne papulosa, pomade acne, premenstral acne, acne pustulosa, acne scorbutica, acne scrofulosorum, acne urticata, acne varioliformis, acne venenata, propionic acne, acne excoriee, gram negative acne, steroid acne, and nodulocystic acne.

[00110] In some embodiments, the compositions of the present technology are used in a method for reducing scar formation. The method comprising an effective amount of a composition as defined herein to an area of a subject comprising the scar to be reduced. In some implementations, the compositions and methods of the present technology may minimize scarred tissue, minimize redness of the scar, reduce fibrous tissue, flatten raised scar area, or improve collagen production in the area of the scar.

[00111] In some embodiments, the compositions of present technology are used in a method for preventing and/or treating atopic dermatitis. The method comprising administering an effective amount of the compositions of the present technology to an area of a subject afflicted by atopic dermatitis. As used herein“atopic dermatitis” comprises a skin disease commonly known as eczema. Atopic dermatitis generally manifests as dry skin, itching, which may be severe, or mild, red to brownish-gray patches, especially on the hands, feet, ankles, wrists, neck, upper chest, eyelids, inside the bend of the elbows and knees, small raised bumps which may leak fluid and crust over when scratched, thickened, cracked, scaly skin, raw, sensitive, swollen skin from scratching etc... The compositions and methods of the disclosure may be used to treat both acute and chronic atopic dermatitis.

[00112] In some embodiments, the compositions of the present technology are used in a method for reducing pain. The method comprising an effective amount of a composition as defined herein to an area of a subject afflicted with pain. In some implementations of these embodiments, the compositions of the present technology is absorbed into deep tissue resulting in instant pain relief in muscle and joints (anti-inflammatory).

[00113] In some embodiments, the compositions of the present technology are used in a method for hair and/or scalp repair. The method comprising an effective amount of a composition as defined herein to hair and/or scalp of the subject. In some implementations of these embodiments, the compositions and methods of the present disclosure may prevent or reduce hair loss, may accelerate hair growth, may assist in the healing of scalp lesions, scalp psoriasis, scalp eczema, may assist in restoring damaged hair, may regulate sebum production, may restore shine, or the like.

[00114] In some embodiments, the compositions of the present technology are used in a method for relieving allergic reactions, the method comprising administering an effective amount of a composition as defined herein to a subject. In some implementations of these embodiments, the composition and methods of the present disclosure may relieve allergic reactions manifesting as sneezing, itchy, runny or blocked nose (allergic rhinitis), itchy, red, watering eyes (conjunctivitis), a raised, itchy, red rash (hives), swollen lips, tongue, eyes or face, tummy pain, feeling sick, vomiting or diarrhoea dry, as well as red and cracked skin,

v) Formulations and Kits

[00115] In some embodiments, the compositions as defined herein are formulated in a dosage form selected from a group consisting of liquid, solid, gas, oral, pill, tablet, capsule, buccal, sub- lingual, orally-disintegrating, thin film, liquid solution, suspension, powder or liquid or solid crystals, pastes, inhalational, aerosol, inhaler, nebulizer, smoking, vaporizer, parenteral, intradermal, intramuscular, intraosseous, intraperitoneal, intravenous, subcutaneous, topical, cream, gel, liniment or balm, lotion, ointment, drops, skin patch, vaginal, suppository, pessary, rectal and any combination thereof. In some embodiments the compositions defined herein are formulated in any form suitable for injection.

[00116] In some implementations of these embodiment, the composition is in a sustained release dosage form or in an immediate release dosage form. Examples of sustained release dosage form include, but are not limited to, drug polymer conjugates, microencapsulation, controlled-release tablet coating, and any combination thereof.

[00117] In some embodiments, the compositions of the present technology are suitable for oral administration. In some implementations of these embodiments, the composition may be formulated into a food item or a beverage item. The compositions suitable for oral administration may also be formulated into capsules or into gels. A carrier oil may be included in the composition in order to facilitate oral ingestion.

[00118] In some further embodiments, the present technology provides for kits. In some implementations of these embodiments, the kit comprises a composition comprising at least one cannabinoid and at least one absorbable material.

[00119] The composition may be provided in the kit in one container or may be provided in separate containers, the content of which is mixed prior to administration. In the instances where the composition is provided in separate containers, one container may comprise the cannabinoid and the container may comprise the absorbable material and the content of the containers may be mixed prior to administration. In some instances, the kit comprises instructions on how to use the kit and how to administer the composition. The kit may comprise at least one component, the at least one component comprising the composition to be administered. The kit may also comprise at least two components, a first component comprising the cannabinoid and a second component comprising the absorbable material. The content of the first and the second components may be mixed prior to administration of the composition. In some instances, the kit comprises instructions on how to use the kit and how to administer the composition.

[00120] Identification of equivalent compositions, methods and kits are well within the skill of the ordinary practitioner and would require no more than routine experimentation, in light of the teachings of the present disclosure. Practice of the disclosure will be still more fully understood from the following examples, which are presented herein for illustration only and should not be construed as limiting the disclosure in any way.

EXAMPLES

[00121] The examples below are given so as to illustrate the practice of various embodiments of the present technology. They are not intended to limit or define the entire scope of this technology. It should be appreciated that the technology is not limited to the particular embodiments described and illustrated herein but includes all modifications and variations falling within the scope of the disclosure as defined in the appended embodiments.

Example 1: Preparation of Cosmetic Composition for Skin Rejuvenation

[00122] A 100 ml composition suitable for topical application comprising a balanced ratio of tetrahydrocannabidiol (THC) to cannabidiol (CBD) of 1:1 was prepared as follows: 5 ml of 99% concentrated Cannabis oil with high THC content was mixed with 5ml of 99% concentrated Cannabis oil with high CBD content; 90ml of 1% high molecular weight hyaluronic acid (HA) (1.0 MDa - 1.5 MDa) serum (GNO: Water, Leuconostoc/Radish Root Ferment Filtrate, Sodium Hyaluronate), and 10 drops of of essential oil. The hyaluronic serum was prepared by mixing 1.0 gram of HA 1.0 MDa - 1.5 MDa in 97 ml of distilled water and 2 ml of a water/leuconostoc/radish root ferment filtrate/ Sodium Hyaluronate solution. HA was sprinkled on the surface of water and mixed well with paddle mixer until the mixture was smooth and evenly hydrated. The composition of the present technology, or a composition comprising THC and CBD but no HA as control was applied to the skin of 10 subjects once a day for two weeks. Use of the composition comprising THC, CBD and HA resulted in smoothing of the skin, and reduction of fine lines and wrinkles, brightening of the skin, improvement in hydration and reduction of sebum production, no change was reported following application of the control composition.

Example 2: Preparation of Cosmetic Composition for Skin Rejuvenation

[00123] A composition suitable for topical application was prepared by mixing 7 ml of full spectrum cannabis oil containing CBD, THC and terpenes (Table I and Figure 1) into 100 ml of 1% HA serum, containing a mixutre of ultra-low, low and high molecular weight HA (6000, 50,000, 100,000, 800,000 and 1,000,000 daltons), for 24 hours.

TABLE 1: Certifcate of analysis of camabinoids in cannabis oil used for topical composition by HPLC

[00124] The composition of the present technology or the control composition described above, was applied to the skin of the face and eye area of 10 subjects twice daily for 7 days. Skin was noticeably tighter, smoother and fine lines and wrinkles disappeared after the treatment. No effect was observed following application of the control composition with no HA.

Example 3: Preparation of Topical Composition for Atopic Dermatitis

[00125] A composition suitable for topical application was prepared by mixing 7 ml of full spectrum cannabis oil containing CBD, THC and terpenes (Table I and Figure 1) into 100 ml of 1% HA serum, containing a mixutre of low and high molecular weight HA (50,000 , 100,000 , 800,000 and 1,000,000 daltons), for 24 hours. 10 human volunteers suffering from atopic dermatitis participated in this study. The composition was applied to the afflicted skin area twice daily. All subjects reported the disappearance of atopic dermatitis after 4 applications, i.e. 2 days. No effect was observed following application of the control composition with no HA.

Example 4: Preparation of Intranasal Composition for Allergy

[00126] A composition suitable for intranasal administration was prepared by mixing 7 ml of full spectrum cannabis oil containing CBD, THC and terpenes (Table I and Figure 1) into 100 ml of 1% HA serum, containing ultra-low and low molecular weight HA (6000, 50,000 and 100,000 daltons), for 24 hours. lOhuman volunteers suffering from allergies, manifesting as severe skin rash, participated in this study. The composition was administered in the form of a nasal spray at 0.1 ml/nostril. Subjects reported relief from itch and redness from rash within 3 minutes (h=10. No effect was observed following application of the control composition with no HA, .

Example 5: Preparation of Composition for Reduction of Hair loss (Hair and/or Scalp repair)

[00127] A 100 ml composition suitable for topical application comprising a balanced ratio of tetrahydrocannabidiol (THC) to cannabidiol (CBD) of 1:1 was prepared as follows: 2.5 ml of 99% concentrated Cannabis oil with high THC content was mixed with 2.5 ml of 99% concentrated Cannabis oil with high CBD content, in 50 ml of 1% high molecular weight hyaluronic acid (HA) (1.0 MDa - 1.5 MDa) serum (INCI: Water, Leuconostoc/Radish Root Foment Filtrate, Sodium

Hyaluronate), and 10 drops of essential oils or cream/lotion. The hyaluronic serum was prepared by mixing 1.0 gram of HA 1.0 MDa - 1.5 MDa in 97 ml of distilled water and 2 ml of a water/leuconostoc/radish root ferment filtrate/Sodium Hyaluronate solution. The hyaluronic acid was sprinkled on the surface of water and mixed well with a paddle mixer until the mixture was smooth and evenly hydrated. The composition, or a composition comprising THC and CBD but no HA as control, was applied to the hair and to the scalp of 20 subjects experiencing hair loss (loss of about 100 hair a day). The composition was applied to the hair and the scalp of the subjects as a conditioner once a day for a period of two weeks. Following treatment, hair loss was significantly reduced or halted by about 90% (loss about 5-10 hair per day) in patients receiving the composition comprising THC, CBD and HA. No effect was observed following application of the control composition with no HA .

Example 6: Preparation of Composition for Reduction of Hair loss (Hair and/or Scalp repair)

[00128] A composition suitable for topical application was prepared by mixing 7 ml of full spectrum cannabis oil containing CBD, THC and terpenes (Table I and Figure 1) into 100 ml of 1% hyaluronic acid serum, containing ultra-low and low molecular weight hyaluronic acid (6000, 50,000, and 100,000 daltons), for 24 hours. 20 human volunteers experiencing hair loss participated in this study. The composition was further added to 15 ml of distilled water and applied with a spray bottle on washed wet hair and scalp once daily. After washing hair normally, hair was combed and lost hair was collected and counted. 100% of subjects reported reduced hair loss by 95% after first application of the composition comprising CBD, THC and HA, as well as new hair growth in thinned areas. The rate of hair growth in all subjects also accelerated from 1.25 cm/ month (about 0.3 cm/week) to 0.5 cm/week. No effect was observed following application of the control composition with no HA .

Example 7: Preparation and Assessment of Oral Composition [00129] A composition suitable for oral administration was prepared by mixing 4 drops of high THC /low CBD cannabis oil (Table 2) with 10 ml of a 1% HA solution, containing ultra-low and low molecular weight HA (6000, 50,000, and 100,000 daltons). A group of 20 human volunteers participated in this study to determine the onset time and duration of the oral composition of the present technology following ingestion. When ingesting the composition comprising high THC/low CBD/HA, 100% of subjects reported onset times of undo- 10 minutes, full effect of the solution at 20-minutes, and a duration of 2 hours . When the same ubjects ingested the control composition comprising high THC/low CBD without HA, the onset times reported were of 2 hours .

Example 8: Preparation of Oral Composition for Reduction of Pain

[00130] A composition suitable for oral administration was prepared by mixing 3 ml of Cannabis oil containing CBD, THC and terpenes (Table I, Figure 1) with 100 ml of a 1% HA solution containing low and high molecular weight HA (50,000, 80,000, 1,000,000 daltons), and lml of glycerin for 24 hours. A group of 3 large dogs aged 10 -12 (two labrador retrievers aged 10 years and 11 years, one border collie, aged 12 years) participated in this study. All dogs had difficulty walking due to pain, demonstrated decreased appetite, and lethargy secondary to joint pain in the hip and knee. Dogs received 10-15 drops of the oral composition, twice daily. All dogs were able to walk better, were no longer limping, and demonstrated increased energy and appetite as early as the second administered dose. After two weeks, dogs were running and playing as normal and demonstrated no sign of pain. One dog, receiving the oral composition for a year, demonstrated no sign of pain evidenced by ha- ability to run daily and a reduction in size of multiple lipomas.

INCORPORATION BY REFERENCE

[00131] All references cited in this specification, and their references, are incorporated by reference herein in their entirety where appropriate for teachings of additional or alternative details, features, and/or technical background.

EQUIVALENTS

[00132] While the disclosure has been particularly shown and described with reference to particular embodiments, it will be appreciated that variations of the above-disclosed and other features and functions, or alternatives thoeof, may be desirably combined into many other different systems or applications. Also, that various presently unforeseen or unanticipated alternatives, modifications, variations or improvements therein may be subsequently made by those skilled in the art which are also intended to be encompassed by the following embodiments.

Claims

CLAIMS:

1. A composition comprising:

- at lent one cannabinoid, wherein thp at li one cannabinoid is isolated from Cannabis or is synthetically derived;

- at least one absorbable material.

2. The compoeitk» according to claim 1, wherein the at least one cannabinoid is selected from: ASMetrahydrocannabinol (THC), cannabidiol (CBD), caimabichromene (CBC), cannabigeral (CBO), cannabinol (CBN), oannabidlvarin (CBDV), among other compounds, oaonablgerollo aold (CBOA), oannablgerolic acid monomethyietlier (CBO AM), caimabigerol monoethylether (CBOM), cannabigerovarmic acid (CBOVA), cannabigerovarln (CBOV), caimabichromemic ack (CBCA), carmabichromevarinic aold (CBCVA), eannabtohromevaHn (CBCVX cannabidiol lo aold (CBDA), cannabidiol monoethylether (CBDM), oannabidiol-C* (CBD-C*), cannabidivarinic acid (CBDV AX oannabidiorcol (CBD-CiX ddta-94etrahydiocannabinolk acid A (THCA-AX delt&r9- tetrahydrocannabinoHc add B (THCA-BX ddta-9-tetrahydrocannablnoIto aoid-Ci (THCA-C«X delta- 94etrafaydrocannabivarlnk add (THCVAX delt^S-tetrabydrocannabivarm (THCVX deha-9- tctrahydrooaimabiorcohc acid (THCA-C|), deha-9-tBtraliydiocannabioicol (THGCiX deita-7-cfr- iso-tetmhydrocannabivarin, deha-S-tetrahydrocinnabinolic add (A'-THCAX deHa-8- tetrahydrooannabinol (D'-THC), cannablpyclollo add (CBLA), cannabicyclol (CBLX cannabkydovarln (CBLVX oannabklaoie acid A (CBBA-AX cannabielsoic acid B (CBEA-BX cannableksom (CBB)m cannabinolio add (CBNAX cannabinol metfaylether (CBNMX cannabinol-Ct (CBN-Cs), cannabivarin (CBVX oannabmol-Ci (CBN-Cy, cannabiorcol (CBN-CiX oannablnodiol (CBNDX caimabinodivarin (CBVDX cannabitrioi (CBTX 1 O-ethosy-P-hydroxy-delta-da- tetrahydrocannabinol, 8,9-dihydroxy-delta-6e-tetrahydrocanntbinol, oannabitriolvarin (CBTVX ethoxy-oaimabhriolvarin (CBTVBX dehydrooennabMUren (DCBFX cannabifuran (CBFX cannabkhromanon (CBCN), oannabkitran (CBO, lO-oxo^kha-dartetrahydracannablnol (OTHCX deha-9-cfr-tetrahydroeannabinol (cir-THC), 3 ,4,5,64otmhydtt)-7-hydroxy-alpha-tlphar2-trimcthyl- 9-n-propyl-2,6-methano-2H-l-benzoxocin-5-methanol (OH-iso-HHCVX cannabiripsol (CBR), and trihydroxy-delta-9-tetrahydrooaiinabinol (triOH-THC).

3. The composition according to claim 1, wherdn the at least one cannabinoid is tetrahydrocannabinol (THC). 4, The competition according to claim I, wherein the at least one cmnabinoid is oannabidiol (CBD),

5. The composition according to claim 1, wherein the at least one oannablnoid ½ a mixture of THC and CBD. 6. The composition according to claim 5, wherein the ratio of THC to CBD in the mixture

Is about 1:1.

7. The composition according to claim 1, wherein the at least one cannabinoid is tetrahydrocannabinol (THC) and is present in the composition in an amount ringing between about 0.001 wt)6 and about 99.999 wt¼ of the total weight of the composition. 8. The composition according to claim 1, wherein die at least one cannabinoid is tetrahydrocannabinol (THC) and is present in the composition in an amount ranging between about 0.001 wt)6 and about 75 wt½ of the total weight of the composition.

9. The composition according to claim I, wherein the at least one carmablnold is tetrahydrocannabinol (THC) and is present in the composition in an amount ranging between about 0.001 wt% and about 30 wtM of the total weight of the composition.

10. The composition according to claim 1, wherein the at least one oannabinoid is oannabidiol (CBD) and is present In the composition in an amount ranging from between about 0.001 wt¾ and about 99.999 wt% of the total weight of the composition,

11. The composition according to claim 1, wherein the at least one cannabinoid is oannabidiol (CBD) and is present in the composition in an amount ranging from between about 0.001 wt% and about 50 wt% of the total weight of tilt composition.

12. The composition according to claim 1, wherein the at least one cannabinoid Is oannabidiol (CBD) and is present in the composition in an amount ranging from between about 0.001 w06 and about 20 wt¼ of the total weight of the composition. 13. The composition according to claim 1, wherein the composition comprises a high THC, low CBD content

14, The composition according to claim 13, wherein the composition comprises between about 10)6 and about 30)6 THC and trace amounts of CBD.

15. The composition according to claim 1, wherein the composition comprii a balanced

CBD/THC content

16. The composition according to claim 15, wherein the composition comprises between about 5% and about 1594 THC and between about 594 and about 15% CBD. 17, The composition according to claim 1, wherein the composition comprises a high CBD, low THC content

18. The composition according to claim 17, wherein the composition comprises between about 5% and about 20% CBD and under about 5% THC.

19. The composition according to any one of claims 1 to 18, wherein die at least one absorbable material ½ a glycosammoglyoan,

20. The composition according to claim 19, wherein the gtycosaminoglyoan is hyaluronic add.

21. The composition according to claim 20, wherein the hyaluronic acid is non cross-linked.

22. The composition according to claim 20, wherein the hyaluronic add is cross-linked. 23. The composition according to claim 20, wherein the hyaluronic add has a molecular weight of between about 5 kDa and about 4.0 MDa, between about 5 kDa and about 1.5 MDa, between about 8 kDa and about 1.5 MDa, between about 80 kDa and about 1.5 MDa, between about 5 kDa and about 110 kDa, between about 8 kDa and about 110 kDa, between about 80 kDa and about 110 kDa, between about 5 kDa and about 1.0 MDa, between about 8 kDa and about 1.0 MDa, between about 100 kDa and about 1.5 MDa, between about 1.0 MDa and about 1,5 MDa, below about 110 kDa, above about 80 kDa, or below about 1.5 MDa.

24. The composition according to claim 20, wherein the hyaluronic acid has a molecular weight comprising a mixture of one or more of. ultra low MW (average of 6000 Da), low (average of 50,000 Da), and high MW (average of 1,000,000 Da). 25. The composition according to any one of claims 1 to 24, wherein the ratio of aannabinoids;HA In the composition is about 1:1 to about 1:100, about 1:1 to about 100:1, about 1:1 to about 1:75, about 1: 1 to about 75, Ί, about 1:1 to about 1:50, about 1:1 to about 50:1, about 1:1 to about 1^5, about 1:1 to about 25:1, about 1:1 to about 1:10, about 1:1 to about 10:1, about 1:1 to about 1:9, about 1:1 to about 9:1, about 1:1 to about 1:8, about 1:1 to about 8:1, about 1:1 to about 1;7, about 1:1 to about 7:1, about 1:1 to about 1:6, about 1:1 to about 6:1, about 1:1 to about 1:5, about 1:1 to about 5:1, about 1:1 to about 1:4, about 1:1 to about 4:1, about 1:1 to about 1:3, about 1:1 to about 3:1, about 1:1 to about 1:2, about 1:1 to about 2:1, about 1:1 to more than about 1:100, about 1:1 to more than about 100:1..

26. The composition according to any one of claims 1 to 25, wherein the composition Author comprises one or more additional ingredient,

27. The composition according to claim 26, wherein the one or more additional Ingredient Is selected from: a hydrophobic carrier, a skin penetrating enhancer, a solvent, a carrier, an excipient; a humectant, an emulsifier, a surfactant, a preservative, a pH adjustor, a fragrance, a dye, a thickener, and a finishing agent

28. The composition according to any one of claims l to 27, whereto the composition is suitable for topical administration.

29. The composition according to any one of claims 1 to 27, wherein the composition is a cosmetic composition.

30. The composition according to any one of claims 1 to 27, wherein die composition is suitable for oral administration.

31 , The composition according to any one of claims 1 to 27, wherein the composition ½ formulated into a food Item. 32. The composition according to any one of claims 1 to 27, wherein the composition Is formulated into a beverage.

33. The composition according to claim 32, wherein the beverage la a non-alcoholic beverage.

34. The composition according to claim 32, wherein the beverage Is an alcoholic beverage. 35. The composition according to any one of claims 1 to 27, wherein the composition is suitable for intranasal administration.

36. The composition according to claim 35, wherein the intranasal administration is by nasal

* .

spray.

*

37. Use of the compositions as defined to any one of claims I to 27 for diminishing the effects of akin aging, preventing the effects of skin aging, or for both, in a subject 38. Use of the compositions as defined to any one of claims 1 to 27 for achieving skin rejuvenation in a subject

39. Use of the compositions as defined in any one of claims 1 to 27 for prevention and/or treatment of acne in a subject

.·

40. Use of the compositions as defined to any one of claims 1 to 27 for prevention and/or treatment of atopio dermatitis in a subject

41. Use of the compositions as defined in any one of claims 1 to 27 for treatment of allergies In a subject.

42. Use of the compositions as defined In olaJm 41 wherein the allergy is skin allergy.

43. Use of the compositions as defined to any one of claims 1 to 27 for reduction of hair loss and/or promoting of hair growth in a subject

44. Use of the compositions as defined In any one of claims 1 to 27 for reduction of pain.

45. Use of the compositions as defined in claim 44, wherein the pain is joint pain.

46. A method for diminishing the efforts of skin aging, preventing the effects of skin aging, or for both, in a subject; the method comprising topically administering a composition as defined to any one of claims 1 to 27 to the subject 47. A method for achieving skin rejuvenation in a subject; the method comprising topically administering a composition as defined to spy one of claims I to 27 to the subject 4g. A method for preventing or treating acne in a subject, the method comprising topically administering a composition as defined in any ooe of claims 1 to 27 to the subject

49. A method for preventing or treating atopic dermatitis In a subject, the method comprising topically administering a composition as defined in any one of claims 1 to 27 to the subject

50. A method for treating allergies in a subject, the method comprising intranasally administering a composition as defined in apy one of claims 1 to 27 to the subject

51. A method for reducing hair loss and promoting hair growth in a subject, the method comprising topically administering a composition as defined In any one of claims 1 to 27 to the subject

52. A method for reducing pain In a subject the method comprising orally administering a composition as defined in any one of claims 1 to 27 to the subject

53. A kit comprising at least one cannabinoid and at least one abaoiheble material and instructions on how to use the kit

54. A kit comprises a first component comprising at least one cannabinolds, a second component comprising at least one abeoibable material; and instructions on how to use the kit

55. The kit according to claim 53 or 54, wherein the the at least one cannabinoid Is selected from; A9-tetra hydrocan nabfnol (THCX cannabidiol (CBD), cannabichromene (CBC), cannabigerol (CBQX oannsbinol (CBN), cannabidlvarln (CBDV), among other compounds, cannabigorolic acid (CBGA), cannabigcrolic acid mooomethylottier (CBGAMX cannabigerol monoethylether (CBGM), cannabigcrovarinic acid (CBGYAX cannablgerovarin (CBGV), cannabichromernic actc (CBCAX cannabichromevarinic acid (CBCVA), eannabiohromevarin (CBCV), cannabkHollo acid (CBDAX cannabidiol monoethylether (CBDM), cannabidioi-Q (CBD-C«X cannabidivarinic add (CBDV A), oannabldiorool (CBD-CiX deHa-9-tetrahydrocannabinol ic acid A (THCA-A), deha-9- tetrahydrooannablnollc acid B (THCA-BX delta-9-tetrahydrocannablnoHo aoid-C, (THGA-QX delta- 9-tetrahydrocannabivarinic acid (THCVAX detia-9-tetrehydrocamiablvarln (THCVX dette-9- tetrahydrocannabiorcolic acid (THCA-CiX deIta-9-tetrahydrocannabiorool (THC-C_|), delta-7-ctr- iso-tetrahydrocannabivarin, delta-8-tetrahydiOcamiabinolic acid (D'-THCA), delta-8- tetrahydrocannabinol (A*-THCX cannabicyclolio acid (CBLA), caimabicyolol (CBL), oannabioyclovarin (CBLV), csnnabtelsoic acid A (CJ3EA-AX oannablelsolc acid B (CBEA-BX cannabieksoin (CBE)m cannabinolic acid (CBN AX cannabinol methylether (CBN MX eannabinol-G* (CBN-QX cannabivarln (CBV), cannabtooI-Cj (CBN-CiX cannabiorooi (CBN-CiX chnnabinodioi (CBNDX oannabiiiodivaiin (CBVDX eannabhriol (CBTX 10-ethoxy-9-hydroxy-delta-6a- tctrahydrocaimabinol, 8,9-dihydroxy-delta-6a-teilrahydrocamiabinol, cannabitriolvarin (CBTVX ethoxy-can nabi trio Ivarin (CBTVEX dehydrocannablflmm (DCBFX oannabtfbian (CBFX cannabichromanon (CBCNX crnmabiciban (CBTX IOoxo-deHa-6a4etiahydrocannabinol (OTHCX delta-9-cif-tetrahydrocaimabinol (cfe-THC), 3,4,5,6-tetrahydn>-7-hydTX)xy-aJpharalphar2-trimethyi- 9-n-propyX2,6-methano-2H- 1 -benzoxoc to-5-methanol (OH-lso-HHCVX cannabiripsol (CBRX and trihydroxy-delta4Metrahydrocanra*inol (triOH-THC).

56. The kit according to claim 53 or 54, wherein the at least one amnebinoid is tetrahydrocannabinol (THC).

57. The kit according to claim 53 or 54, wherein the at least one aannablnoid Is cannabidioi (GBD).

58. The kit acoordmg to claim 53 or 54, wherein the at least one eannabinoid Is a mixture of

THC and CBD.

59. The kit according to claim 53 or 54, wherein the at least one eannabinoid Is tetrahydrocannabinol (THC) and is present in the composition In an amount ranging between about 0.001 wt¾4 and about 99.999 wt% of the total weight of the composition.

60. The kit according to claim 53 or 54, wherein the at least one eannabinoid is tetrahydrocannabinol (THC) and Is present in the composition in an amount ranging between about 0.001 wt¾ and about 75 wt% of the total weight of the composition.

61. The kit according to claim 53 or 54, wherein die at least one eannabinoid is tetrahydrocannabinol (THC) and is present in the composition in an amount ranging between about 0,001 wt% and about 30 wt% of the total weight of the composition,

62, The kit according to claim 53 or 54, wherein the at least one eannabinoid is cannabidioi (CBD) and is present in the composition in an amount ranging from between about 0.001 wt% mid about 99.999 wtM of the total weight of the composition.

63. The kit according to claim 53 or 54, wherein the at least one cannabinoid la cannibidlol

(CBD) and is present in the composition in an amount ranging from between about 0.001 wt¾ and about 50 wt¾ of the total weight of the composition.

64. The kit according to claim S3 or 54, wherein the at least one cannabinoid is cannabidiol (CBD) and is present in the composition in an amount ranging from between about 0.001 wtM and about 20 wf% of the total weight of the composition.

65. The kit according to any one of claims 53 to 54, wherein the at least one absorbable material is a giycosaminoglycan.

66. The kit according to claim 65, wherein the giycosaminoglycan is hyaluronic acid.' 67. The kit according to claim 66^ wherein the hyaluronic add is non cresa-1 Inked.

68. The kit according to claim 66 wherein the hyaluronic acid is cross-linked.

69. The kit according to claim 66, wherein the hyaluronic acid has a molecular weight of between about 5 kDa and about 4.0 MDa, between about 5 kDa and about 1.5 MDa, between about 8 kDa and about 1.5 MDa, between about 80 kDa and about 1.5 MDa, between about 5 kDa and about 110 kDa, between about 8 kDa and about 110 kDa, between about 80 kDa and about 110 kDa, between about 5 kDa and about 1.0 MDa, between about 8 kDa and about 1.0 MDa, between about 100 kDa and about 1.5 MDa, between about 1.0 MDa and about U MDa, below about 110 kDa, above about 80 kDa, or below about 1.5 MDa.

70. The kit according to claim 66, wherein the ratio of cannabinoids:HA in the kit is about 1:1 to about 1:100, about 1:1 to about 100:1, about 1:1 to about 1:75, about 1:1 to about 75:1, about

1:1 to about 1:50, about 1:1 to about 50:1, about 1:1 to about 155, about 1 :1 to about 25: l, about 1:1 to about 1: 10, about 1:1 to about 10:1, about 1:1 to about 1:9, about 1:1 to about 9:1, about 1:1 to about 1:8, about 1:1 to about 8:1, about 1:1 to about 1:7, about 1:1 to about 7:1, about 1:1 to about 1:6, about 1:1 to about 6:1, about 1:1 to about 1:5, about 1:1 to about 5:1, about 1:1 to about 1:4, about 1:1 to about 4:1, about 1:1 to about 1:3, about 1:1 to about 3:1, about 1:1 to about 13, about 1:1 to about 2:l, about 1:1 to more than about 1:100, about 1:1 to more than about 100:1..

71. The kit according to any one of claims 53 to 01, wherein the kit farther comprises one or more additional ingredient

72. The kit according to claim 71, wherein the one or more additional ingredient is selected from: a hydrophobic carrier, a skin penetrating enhancer, a solvent, a carrier, an excipient, a humectant, an emulsifier, a surfactant, a preservative, a pH adjuster, a fragrance, a dye, a thickener, and a finishing agent 73. A beverage oomprlsing:

- at least one oannabinoid, wherein the at least one caimabinold is Isolated from Cannabis or is synthetically derived;

- at least one absorbable material.

74. The beverage according to olalm 73, wherein the beverage is non-alcoholic, 75. The beverage according to claim 73, wherein the beverage Is alcoholic.

76. A composition oomprlsing:

- at least one oannabinoid, wherein the at least one cannabinoid is isolated from Cannabis or is synthetically derived;

- at least one absorbable material;

- at least one terpene; and

- at least one botanical extract